{"meta":{"query_hash":"3276d03249a7","filters":{"venue":"Inpharma Weekly"},"cohort_total":85,"direct_labels_cover":0,"predictions_cover":85,"exported":85,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/3276d03249a7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Inpharma+Weekly"},"results":[{"id":"W1986963851","doi":"10.2165/00128413-200213280-00030","title":"Canadian study supports alteplase use outside tertiary care setting","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tertiary care; Pharmacy; Medical emergency; Family medicine","score_opus":0.01805097595681214,"score_gpt":0.2690910662904095,"score_spread":0.25104009033359737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986963851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97813237,0.0004027683,0.0000012708023,0.0056300447,0.00033576848,0.0007888398,0.000029827559,0.00013351378,0.014545602],"genre_scores_gemma":[0.98482925,0.00002196816,0.00008542506,0.0056880536,0.00028442833,0.000033082826,0.000039804545,0.000046581754,0.008971436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816847,0.00013015489,0.00036659357,0.0003733395,0.0003901976,0.0005712504],"domain_scores_gemma":[0.9983261,0.000256203,0.00005383271,0.0004182467,0.00010071905,0.0008448683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020303323,0.0002478611,0.0005089974,0.00022543175,0.00015228982,0.000071629554,0.000100853955,0.00009186582,0.0015445193],"category_scores_gemma":[0.00016251452,0.00021542046,0.0002986599,0.00016505901,0.00003461093,0.00018098856,0.000030616317,0.00028935506,0.00047492425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024228922,0.0001369176,0.95675796,0.00003588699,0.00011290735,0.013855684,0.0030978932,0.000004789709,0.00007149804,0.0000071302716,0.018878568,0.0070165107],"study_design_scores_gemma":[0.0023117454,0.00016148726,0.7123359,0.000043959582,0.00033462298,0.0007348518,0.0034677135,0.00010215136,0.00024406212,8.324058e-7,0.2799303,0.0003323785],"about_ca_topic_score_codex":0.0395141,"about_ca_topic_score_gemma":0.012869105,"teacher_disagreement_score":0.26105174,"about_ca_system_score_codex":0.00024467768,"about_ca_system_score_gemma":0.00011617937,"threshold_uncertainty_score":0.9993682},"labels":[],"label_agreement":null},{"id":"W2031093133","doi":"10.2165/00128413-200213260-00017","title":"Best case needed to see oseltamivir's value for flu in Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oseltamivir; Medicine; Value (mathematics); Pharmacy; Virology; Coronavirus disease 2019 (COVID-19); Statistics; Family medicine; Internal medicine; Mathematics; Infectious disease (medical specialty)","score_opus":0.04792130752394808,"score_gpt":0.29574083098371967,"score_spread":0.2478195234597716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031093133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835556,0.00045988473,0.00004192762,0.009447334,0.00046779827,0.0010308758,0.00013948265,0.000041738345,0.004815355],"genre_scores_gemma":[0.98633987,0.00005909407,0.00075820996,0.009302309,0.00027708907,0.0002144695,0.000006825865,0.0000416565,0.003000482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985609,0.00003663174,0.00035052904,0.00029399156,0.00025649858,0.0005014466],"domain_scores_gemma":[0.9991405,0.00018059819,0.000042986972,0.00024248884,0.00010912364,0.00028429923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013559859,0.00019780708,0.00038287853,0.00014151973,0.000101339734,0.000013282032,0.00009206797,0.000047173802,0.00034090647],"category_scores_gemma":[0.00029839884,0.00019618239,0.000055727913,0.0003212973,0.000024891719,0.0000682493,0.000059402097,0.00017492367,0.00025880506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020219092,0.00041553727,0.09564565,0.00032667126,0.0002052981,0.01952463,0.004387879,0.00014966207,0.007435538,0.00007468424,0.8379481,0.03368419],"study_design_scores_gemma":[0.013529759,0.0013796148,0.027105015,0.00057585334,0.0004440358,0.0038974842,0.0054614954,0.012803826,0.019812908,0.000045580025,0.9135107,0.0014337617],"about_ca_topic_score_codex":0.9662168,"about_ca_topic_score_gemma":0.97423816,"teacher_disagreement_score":0.0755626,"about_ca_system_score_codex":0.0007490849,"about_ca_system_score_gemma":0.00029937012,"threshold_uncertainty_score":0.8000086},"labels":[],"label_agreement":null},{"id":"W2059851348","doi":"10.2165/00128413-200112810-00011","title":"Canada chooses its weapons in the battle against influenza","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Battle; Medicine; Virology; Ancient history; History","score_opus":0.10522840513394786,"score_gpt":0.38760391904179486,"score_spread":0.282375513907847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059851348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480634,0.0023349584,0.0000013457517,0.013841141,0.00024811644,0.0004994749,0.00004309728,0.00004411958,0.034924358],"genre_scores_gemma":[0.9721918,0.00062460505,0.000022468024,0.025762176,0.00033276362,0.000107457614,0.000008257807,0.000025054018,0.00092542736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791217,0.00013461156,0.00032835815,0.00024883327,0.0007545024,0.0006215017],"domain_scores_gemma":[0.99868935,0.0005759326,0.000052164694,0.00036192837,0.00016597974,0.0001546467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004274701,0.00019864699,0.00027712306,0.00014780584,0.00017091559,0.000033905948,0.00031979056,0.000053538555,0.00031215034],"category_scores_gemma":[0.0010344338,0.00013591284,0.000060383387,0.0006027654,0.00009445632,0.0001305823,0.00010549987,0.00053935946,0.00021283393],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009023196,0.00051787245,0.20097122,0.00021762762,0.0003008178,0.0043133735,0.0021298626,0.00025236595,0.017244447,0.0002428042,0.7552879,0.017619409],"study_design_scores_gemma":[0.001917005,0.000063090214,0.20752692,0.00006639352,0.00002094141,0.000042387648,0.00084435864,0.00010366239,0.001688469,0.000006870885,0.78756803,0.00015185775],"about_ca_topic_score_codex":0.15349136,"about_ca_topic_score_gemma":0.17357437,"teacher_disagreement_score":0.033998933,"about_ca_system_score_codex":0.0003046691,"about_ca_system_score_gemma":0.0009948259,"threshold_uncertainty_score":0.8521456},"labels":[],"label_agreement":null},{"id":"W4205152399","doi":"10.2165/00128413-200514830-00035","title":"Is it bye-bye Bextra in the US, EU and Canada?","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Infective Endocarditis Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.022279634870454524,"score_gpt":0.3001602326206158,"score_spread":0.2778805977501613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205152399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8666199,0.00067888125,0.000016638232,0.0735906,0.00021146235,0.0005175934,0.000023571052,0.000017218988,0.058324132],"genre_scores_gemma":[0.9280846,0.00048307513,0.000057026675,0.070482455,0.00035905442,0.00006266167,0.0000075761327,0.00001169177,0.00045183548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906576,0.000049796272,0.00017431682,0.00019349504,0.0002688147,0.00024784077],"domain_scores_gemma":[0.99959713,0.000078060904,0.0000344733,0.0001826725,0.00003443314,0.00007321422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024135874,0.00012082869,0.00017378465,0.0000585427,0.000060090555,0.000025878633,0.00008391227,0.000028176442,0.00051627285],"category_scores_gemma":[0.000032441505,0.00008833638,0.000041827254,0.00009726689,0.000036079517,0.00007547121,0.000039876253,0.00018317642,0.00003951016],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011806008,0.00012290991,0.059621084,0.00003200449,0.000059123857,0.00020549435,0.00055926986,0.000010258931,0.00011850242,0.0004179984,0.92273563,0.01610592],"study_design_scores_gemma":[0.0009514942,0.000044135293,0.34195194,0.000029181188,0.000043486925,0.00003354898,0.00022619913,0.00008066601,0.0005505208,0.000009520416,0.6560046,0.00007472144],"about_ca_topic_score_codex":0.14298896,"about_ca_topic_score_gemma":0.18300003,"teacher_disagreement_score":0.28233087,"about_ca_system_score_codex":0.00013491623,"about_ca_system_score_gemma":0.00009754222,"threshold_uncertainty_score":0.8627179},"labels":[],"label_agreement":null},{"id":"W4205563331","doi":"10.2165/00128413-200514820-00086","title":"Health Canada has approved Pfizer's dalteparin sodium [Fragmin],","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine; Pharmacology","score_opus":0.13165161942589404,"score_gpt":0.4079476999646185,"score_spread":0.27629608053872445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205563331","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089854494,0.0018127077,0.00023303204,0.89127815,0.0005945967,0.0011962971,0.00005127577,0.00014961156,0.014829857],"genre_scores_gemma":[0.8286182,0.000296487,0.00085828773,0.16186719,0.001443086,0.000049199276,0.000066044144,0.000041617935,0.0067598782],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957457,0.00013327462,0.000562901,0.00037562838,0.0012599739,0.00192253],"domain_scores_gemma":[0.9890334,0.00019296558,0.00010890576,0.00042146893,0.00015182613,0.01009146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012973028,0.00022619133,0.00053084164,0.00012299788,0.00026087128,0.00003618894,0.00021094426,0.00010147106,0.00076069287],"category_scores_gemma":[0.0049146,0.0001888434,0.00007122613,0.00030332847,0.00013692988,0.00011864901,0.000071661685,0.00084266934,0.00024833152],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022824814,0.00017431236,0.000552984,0.00026704356,0.000027968974,0.00012740205,0.0001531818,0.0000022294155,0.00050168834,0.000030775784,0.8247365,0.17319767],"study_design_scores_gemma":[0.0032986326,0.0003730152,0.0042463904,0.00011258109,0.000013707539,0.000113320755,0.00008747899,0.0009546812,0.0016002001,0.000011995256,0.9890325,0.000155491],"about_ca_topic_score_codex":0.42036688,"about_ca_topic_score_gemma":0.31742108,"teacher_disagreement_score":0.73876375,"about_ca_system_score_codex":0.0013546739,"about_ca_system_score_gemma":0.04674985,"threshold_uncertainty_score":0.9586542},"labels":[],"label_agreement":null},{"id":"W4210298556","doi":"10.2165/00128413-200615270-00041","title":"Cipher Pharmaceuticals has received final approval from Health Canada for CIP-Fenofibrate,","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fenofibrate; Pharmacy; Drug approval; Pharmacology; Family medicine; Drug","score_opus":0.07076342288765271,"score_gpt":0.37455700265032493,"score_spread":0.30379357976267224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210298556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80519307,0.0068377517,0.004443812,0.15054728,0.002918426,0.005166911,0.003267271,0.0003812599,0.021244207],"genre_scores_gemma":[0.97798854,0.000038034446,0.0044960594,0.007910917,0.0008029549,0.00011812921,0.0010278337,0.00005164637,0.007565867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985582,0.000039871982,0.00036190107,0.00034408708,0.0002626963,0.00043323313],"domain_scores_gemma":[0.9992028,0.00011590299,0.000113439615,0.00019414963,0.00011567229,0.00025806835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088760025,0.00019911454,0.00033921923,0.0000436022,0.0002420945,0.000040848827,0.0000818378,0.000051364983,0.00061122206],"category_scores_gemma":[0.00001712833,0.00017219303,0.00008755745,0.00013959163,0.00005958828,0.00008296829,0.000017062139,0.00012900247,0.000022952856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007282111,0.00046878506,0.003759261,0.0001385472,0.0004317583,0.00008789112,0.00028525686,0.00012516942,0.0062069525,0.00015336464,0.96853155,0.019083224],"study_design_scores_gemma":[0.010399046,0.0003727965,0.019052234,0.000088826026,0.00044146058,0.0000262017,0.00022533096,0.001293208,0.0093027335,0.00045809138,0.9580482,0.00029185807],"about_ca_topic_score_codex":0.45028642,"about_ca_topic_score_gemma":0.114770845,"teacher_disagreement_score":0.3355156,"about_ca_system_score_codex":0.0005476658,"about_ca_system_score_gemma":0.0026594168,"threshold_uncertainty_score":0.90138227},"labels":[],"label_agreement":null},{"id":"W4210528054","doi":"10.2165/00128413-200715730-00068","title":"A pravastatin/aspirin combination therapy [PravASA; Paladin Labs] has been launched in Canada.","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Launched; Medicine; Pravastatin; Aspirin; Pharmacy; Family medicine; Internal medicine; Engineering","score_opus":0.032241837680085705,"score_gpt":0.2847662141551547,"score_spread":0.252524376475069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210528054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887981,0.001411361,0.0003522297,0.005461346,0.0002831397,0.001095625,0.000014728113,0.000058658752,0.0025248327],"genre_scores_gemma":[0.9952214,0.00022461824,0.00034390608,0.003272739,0.00026851293,0.000045403714,0.00006864646,0.000042791624,0.00051202497],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99771273,0.00011682345,0.0004951256,0.00033653248,0.00078690686,0.000551871],"domain_scores_gemma":[0.99894994,0.000076110846,0.00011675453,0.00039958974,0.00016824785,0.00028933087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016049026,0.0002123484,0.00043908774,0.00018111944,0.00008484432,0.00002675423,0.00012508013,0.00009626847,0.00018960865],"category_scores_gemma":[0.00007220276,0.0001926167,0.00011098627,0.00049678236,0.000044616667,0.00009917759,0.000028965573,0.00041957773,0.000030840147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013275425,0.0009921669,0.24291424,0.00047490702,0.000567572,0.0024452277,0.0026027425,0.00003145514,0.026985556,0.0004650679,0.021490805,0.69970274],"study_design_scores_gemma":[0.011824472,0.00036845196,0.7691893,0.00015358921,0.000048361235,0.00012011963,0.0007331468,0.00020617299,0.025176285,0.00009981083,0.19172484,0.00035545178],"about_ca_topic_score_codex":0.6435594,"about_ca_topic_score_gemma":0.61650527,"teacher_disagreement_score":0.69934726,"about_ca_system_score_codex":0.0007560376,"about_ca_system_score_gemma":0.0021925056,"threshold_uncertainty_score":0.7854681},"labels":[],"label_agreement":null},{"id":"W4210872218","doi":"10.2165/00128413-200514960-00047","title":"Health Canada has received four reports of Duragesic [fentanyl] patch abuse by boys aged 14???17 years, between 1 Jan 1998 and 31 Jan 2005,","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fentanyl; Psychiatry; Family medicine; Pediatrics; Anesthesia","score_opus":0.05029089341759819,"score_gpt":0.2915990064071286,"score_spread":0.24130811298953042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210872218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854571,0.00021509171,0.0000066979164,0.013005359,0.00010718892,0.00080858154,0.00012758456,0.000065568034,0.00020680908],"genre_scores_gemma":[0.99231946,0.00052325573,0.000056747453,0.0031546846,0.00016349825,0.00003146257,0.00002022108,0.00005175462,0.0036789398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99618334,0.00046330507,0.0007455697,0.00075766596,0.00097167754,0.0008784213],"domain_scores_gemma":[0.99804574,0.0003725703,0.00041065144,0.00052970566,0.00003650058,0.00060485705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006720994,0.00029116144,0.00054258574,0.00013865178,0.00033779693,0.00009652417,0.0004152214,0.00009894221,0.000092426584],"category_scores_gemma":[0.00018052038,0.00029746888,0.00007748546,0.00036225314,0.000263725,0.00027259008,0.000093264964,0.00058212376,0.000021470423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011859094,0.00019037005,0.050850954,0.00009530481,0.000022230633,0.0018064568,0.000941155,0.000011214448,0.2779821,0.0000019733197,0.6623129,0.0056667267],"study_design_scores_gemma":[0.0019207173,0.00041765673,0.12037758,0.00011588532,0.000033933655,0.0008850651,0.0001384353,0.00017153381,0.38301012,0.000029095105,0.49220306,0.00069690583],"about_ca_topic_score_codex":0.0682336,"about_ca_topic_score_gemma":0.053585257,"teacher_disagreement_score":0.17010988,"about_ca_system_score_codex":0.00020955497,"about_ca_system_score_gemma":0.0008601717,"threshold_uncertainty_score":0.9999477},"labels":[],"label_agreement":null},{"id":"W4212882070","doi":"10.2165/00128413-200715910-00071","title":"Product approvals in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Product (mathematics); Pharmacy; Family medicine; Mathematics","score_opus":0.3321649356588049,"score_gpt":0.42406658912105033,"score_spread":0.09190165346224544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212882070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92475915,0.0025194483,0.00089074677,0.04363343,0.0018017349,0.00088171655,0.00013411738,0.000050442104,0.025329225],"genre_scores_gemma":[0.9835208,0.000033248318,0.0009784997,0.0138506945,0.0004959002,0.00004341995,0.0000155878,0.00003032805,0.0010315349],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952229,0.0001178308,0.0034027388,0.00053715694,0.0001093284,0.0006100148],"domain_scores_gemma":[0.9978288,0.0005084057,0.000994819,0.00042177073,0.000040514,0.00020573255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016404832,0.00016780396,0.0006642546,0.000308317,0.00007595725,0.000032429918,0.00030654253,0.000054836146,0.00061160926],"category_scores_gemma":[0.0015253284,0.00022740483,0.000052763047,0.00032581203,0.000029877328,0.00032238886,0.000042070184,0.00022757052,0.0012192426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043096323,0.00015650404,0.70667654,0.00040247547,0.000063647334,0.000042611864,0.001600654,0.000403295,0.000062279854,0.02634399,0.2609862,0.003218716],"study_design_scores_gemma":[0.0016099374,0.000033726334,0.47036248,0.00006401195,0.0000039382444,0.000020016874,0.001793831,0.0017209707,0.00034342916,0.0048276135,0.51849794,0.0007221243],"about_ca_topic_score_codex":0.8150342,"about_ca_topic_score_gemma":0.7832496,"teacher_disagreement_score":0.2575117,"about_ca_system_score_codex":0.002128053,"about_ca_system_score_gemma":0.0009342765,"threshold_uncertainty_score":0.99955845},"labels":[],"label_agreement":null},{"id":"W4214588361","doi":"10.2165/00128413-200113140-00012","title":"Galantamine treatment for AD warranted in Canada","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Galantamine; Pharmacy; Psychiatry; Pharmacology; Family medicine; Internal medicine; Donepezil; Disease; Dementia","score_opus":0.05737118821012451,"score_gpt":0.33578677960604236,"score_spread":0.27841559139591787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214588361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905087,0.0002869644,0.00014707423,0.007109371,0.00018080011,0.0006687419,0.000033278444,0.000033711338,0.001031402],"genre_scores_gemma":[0.9946059,0.00014582486,0.0001181038,0.0007361006,0.000060617807,0.00011650412,0.0000778986,0.000025364083,0.004113692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991068,0.00002053865,0.0002175609,0.00020992615,0.00016437245,0.0002807881],"domain_scores_gemma":[0.9995384,0.00008722543,0.000046695044,0.00016677217,0.00005866275,0.00010224068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050153783,0.00014086837,0.0002689145,0.00008788247,0.000033041906,0.0000057983452,0.000044207038,0.000034214725,0.00053418346],"category_scores_gemma":[0.000043867665,0.00012311043,0.00006430553,0.00018177033,0.000012521668,0.00006328423,0.000008765615,0.00008239433,0.000033751814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021388533,0.001570752,0.8441579,0.00012337504,0.0002644457,0.0014241245,0.00039491017,0.00012444925,0.044024054,0.000011899724,0.012314222,0.09345106],"study_design_scores_gemma":[0.0251746,0.00070280646,0.6551053,0.00012279523,0.00024114334,0.00064921955,0.003007868,0.008699001,0.002696281,0.000015402322,0.3031083,0.00047728402],"about_ca_topic_score_codex":0.39623025,"about_ca_topic_score_gemma":0.7110784,"teacher_disagreement_score":0.31484815,"about_ca_system_score_codex":0.00069774844,"about_ca_system_score_gemma":0.0005308472,"threshold_uncertainty_score":0.6077903},"labels":[],"label_agreement":null},{"id":"W4229711811","doi":"10.2165/00128413-200515160-00042","title":"Health Canada has advised that it is reviewing if changes to the Canadian Evra [ethinylestradiol/norelgestromin] labelling are required,","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Labelling; Medicine; Ethinylestradiol; Pharmacy; Family medicine; Environmental health; Criminology; Research methodology; Population","score_opus":0.38029838914329867,"score_gpt":0.45772187177370716,"score_spread":0.07742348263040849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229711811","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030170936,0.002061468,0.00009312151,0.96503586,0.0006511601,0.0014093153,0.00018021933,0.00005326241,0.00034467742],"genre_scores_gemma":[0.62869334,0.0008376568,0.001691426,0.3667772,0.0012925847,0.00005373404,0.00007494309,0.000047133683,0.0005319834],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996659,0.000257442,0.001028754,0.00050875114,0.00073879055,0.00080725935],"domain_scores_gemma":[0.99691194,0.00056292827,0.0005231604,0.0006470865,0.00025516885,0.0010996896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021578097,0.00029925007,0.0005661343,0.00013682629,0.0006324972,0.00012146067,0.00034402826,0.00009548775,0.0004922308],"category_scores_gemma":[0.001506561,0.00024334736,0.000093951516,0.0004127585,0.00007036735,0.00022723501,0.000057874764,0.00068837387,0.00013827141],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059814458,0.000030104573,0.0028867223,0.00012190707,0.00007373197,0.00008507308,0.0012872019,0.000095260875,0.00009939513,0.0000076089486,0.913293,0.08196015],"study_design_scores_gemma":[0.0011183477,0.0001359618,0.005579001,0.0005408988,0.00014531103,0.00010807207,0.0019868256,0.0006974076,0.00028695815,0.000006619949,0.98915374,0.00024083146],"about_ca_topic_score_codex":0.9581914,"about_ca_topic_score_gemma":0.99798506,"teacher_disagreement_score":0.59852237,"about_ca_system_score_codex":0.0018516553,"about_ca_system_score_gemma":0.0055388776,"threshold_uncertainty_score":0.9923417},"labels":[],"label_agreement":null},{"id":"W4230288979","doi":"10.2165/00128413-200816200-00047","title":"New warnings for Alertec in Canada","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Risk and Safety Analysis","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.11741756444950902,"score_gpt":0.35446871489658943,"score_spread":0.23705115044708042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230288979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566159,0.00055244006,0.015317693,0.022330316,0.0006773769,0.00026110074,0.000029917115,0.000031336065,0.0041838903],"genre_scores_gemma":[0.9845784,0.0001277364,0.0012964652,0.0009978493,0.00012608066,0.000010056718,0.000003243701,0.000008825766,0.012851372],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790144,0.00006703579,0.0005391257,0.00034589972,0.00084513554,0.0003013855],"domain_scores_gemma":[0.9984576,0.00078597595,0.00013469499,0.0003048725,0.000128234,0.0001885871],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000635549,0.00011174311,0.00029595097,0.00019679077,0.0001418492,0.000031700023,0.0006272406,0.00003568826,0.00095820235],"category_scores_gemma":[0.0007128944,0.000088351335,0.000121618876,0.0008614751,0.000026356029,0.00021206228,0.000049932274,0.00012345302,0.00016756282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061088576,0.000014607896,0.08502142,0.0000013742948,0.000017902685,0.0000871016,0.000935436,0.00094174093,0.00028004884,0.00003555745,0.74101955,0.17158419],"study_design_scores_gemma":[0.0013656017,0.000035989167,0.124792814,0.000007328488,0.000017195458,0.000031553576,0.0007667647,0.020887492,0.0009905508,0.0060933116,0.8447172,0.00029418024],"about_ca_topic_score_codex":0.8370749,"about_ca_topic_score_gemma":0.8621667,"teacher_disagreement_score":0.17129001,"about_ca_system_score_codex":0.00016181539,"about_ca_system_score_gemma":0.0017095121,"threshold_uncertainty_score":0.99995506},"labels":[],"label_agreement":null},{"id":"W4230932386","doi":"10.2165/00128413-200715990-00047","title":"Health Canada has granted expanded approval of lumiracoxib [Prexige; Novartis] for the treatment of acute and chronic osteoarthritis","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Osteoarthritis; Pharmacy; Alternative medicine; Physical therapy; Intensive care medicine; Family medicine","score_opus":0.017770540404014223,"score_gpt":0.29173642141987416,"score_spread":0.27396588101585995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230932386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890147,0.00619989,0.0005998177,0.001797669,0.00043269244,0.0017465826,0.00013336244,0.000019436296,0.00005587039],"genre_scores_gemma":[0.99846125,0.0005587205,0.00016390199,0.00024190519,0.00029098065,0.00007085668,0.000033670072,0.00002404587,0.00015466695],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869096,0.00003164137,0.00046051882,0.0001902231,0.00025680376,0.00036986938],"domain_scores_gemma":[0.99901295,0.0002534083,0.00021536154,0.00023004791,0.00010863869,0.00017957213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035498937,0.0001733346,0.00049714773,0.000066778164,0.00012187001,0.0000056800914,0.00006376172,0.00005425367,0.000020796135],"category_scores_gemma":[0.000019318368,0.00011872657,0.0000975451,0.00013487966,0.0001715516,0.0000360843,0.000011824835,0.00007800208,6.6557493e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060215387,0.0008950658,0.010062445,0.0022227284,0.0015160837,0.0003639,0.0051052608,0.000016278404,0.20300502,0.00012260747,0.019255288,0.75141376],"study_design_scores_gemma":[0.03118721,0.013782129,0.03664337,0.00042255933,0.0007772549,0.00036453007,0.0005576571,0.0011059735,0.8428256,0.00002319453,0.07195442,0.00035608356],"about_ca_topic_score_codex":0.036093224,"about_ca_topic_score_gemma":0.11406332,"teacher_disagreement_score":0.7510577,"about_ca_system_score_codex":0.00023756507,"about_ca_system_score_gemma":0.0011044202,"threshold_uncertainty_score":0.9703255},"labels":[],"label_agreement":null},{"id":"W4231145226","doi":"10.2165/00128413-200414600-00058","title":"Product launches in Canada","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Product (mathematics); Family medicine","score_opus":0.00907366324514077,"score_gpt":0.2266015710834211,"score_spread":0.21752790783828033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231145226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85770684,0.0009797723,0.000008729895,0.13673869,0.0002991142,0.00014981299,0.0000015437504,0.000050288738,0.0040652193],"genre_scores_gemma":[0.9964335,0.00016327058,0.00016514855,0.0026654315,0.0000636501,0.000006291591,0.0000036277606,0.0000074927825,0.0004915889],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994507,0.0000068494396,0.00012618264,0.00014829444,0.00009012735,0.00017788743],"domain_scores_gemma":[0.99975216,0.000007912612,0.000019755269,0.00015176498,0.000017498645,0.00005089713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000055531225,0.000071894596,0.00012742377,0.000062467356,0.000022244636,0.0000016980483,0.000061017134,0.00033302078,0.000105613275],"category_scores_gemma":[0.00003221219,0.000058378595,0.000018391784,0.00019788968,0.000039410937,0.000025609404,0.000017758723,0.0012503911,0.00004591784],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013410222,0.0017375711,0.39421198,0.0007168681,0.0007838534,0.01718081,0.0021110792,0.0012581812,0.25669336,0.012480406,0.17541613,0.13606876],"study_design_scores_gemma":[0.008135019,0.00022240085,0.26609766,0.00035113114,0.00010340842,0.0010013297,0.00060770486,0.000053011387,0.5201369,0.0010671781,0.20176561,0.00045863763],"about_ca_topic_score_codex":0.49261492,"about_ca_topic_score_gemma":0.44530547,"teacher_disagreement_score":0.26344356,"about_ca_system_score_codex":0.00022610143,"about_ca_system_score_gemma":0.0009920573,"threshold_uncertainty_score":0.5648163},"labels":[],"label_agreement":null},{"id":"W4231537586","doi":"10.2165/00128413-200615510-00066","title":"Health Canada has approved rituximab [Rituxan; Roche] as a maintenance therapy for patients with follicular non-Hodgkin's lymphoma","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Oncology; Lymphoma; Hodgkin lymphoma; Maintenance therapy; Internal medicine; Pharmacy; Family medicine; Chemotherapy","score_opus":0.007872528325920655,"score_gpt":0.2359594050837431,"score_spread":0.22808687675782247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231537586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776929,0.0012475887,0.0002686256,0.016223807,0.00027212445,0.0032251568,0.00019280161,0.00008597828,0.00079100457],"genre_scores_gemma":[0.9888663,0.00009615144,0.0016503447,0.0071987314,0.00021707798,0.0008183417,0.0003996986,0.00007621392,0.00067712],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9976558,0.00003696792,0.0004352336,0.0005739241,0.0005631758,0.0007349076],"domain_scores_gemma":[0.9986409,0.000086082015,0.00023757177,0.0004297884,0.00029530757,0.00031036633],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011807585,0.00040335738,0.0007010312,0.00007512703,0.0002764747,0.00006329269,0.00015048079,0.000076849276,0.000032633983],"category_scores_gemma":[0.00001939046,0.00028693778,0.00016010573,0.00022320921,0.00007462569,0.00010239899,0.000025597816,0.000067910645,0.00001866608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006756706,0.018285364,0.26528198,0.0003825162,0.001082298,0.0005940069,0.0003360211,0.000029783308,0.0003340501,0.00036735658,0.576034,0.1305159],"study_design_scores_gemma":[0.11443194,0.003714197,0.45903984,0.00029736405,0.00015290071,0.00008453343,0.00008984589,0.00031375926,0.0053789737,0.00012563812,0.41579756,0.0005734484],"about_ca_topic_score_codex":0.41436642,"about_ca_topic_score_gemma":0.07081407,"teacher_disagreement_score":0.34355235,"about_ca_system_score_codex":0.0011240466,"about_ca_system_score_gemma":0.002384058,"threshold_uncertainty_score":0.9999583},"labels":[],"label_agreement":null},{"id":"W4231741136","doi":"10.2165/00128413-200615540-00012","title":"Ezetimibe add-on to atorvastatin: evidence for adoption in Canada","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Synthesis of β-Lactam Compounds","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ezetimibe; Atorvastatin; Medicine; Pharmacy; Pharmacology; Family medicine; Internal medicine; Statin","score_opus":0.047076522814544865,"score_gpt":0.2926426875188345,"score_spread":0.24556616470428963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231741136","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911389,0.0001204799,0.00009343143,0.0022915627,0.00022595843,0.00019944579,0.00006575277,0.000065139975,0.0057993373],"genre_scores_gemma":[0.99635655,0.000005225046,0.001343598,0.0007594223,0.00038612343,0.00015960181,0.000017745135,0.000041507406,0.0009302435],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984373,0.000022956448,0.000366089,0.00038238204,0.0003740367,0.00041722792],"domain_scores_gemma":[0.99854755,0.00082767557,0.000100813515,0.00032963595,0.000074942414,0.00011940079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016533757,0.0002056057,0.00021480722,0.00007988771,0.000059806236,0.000042131604,0.00033657864,0.00005710597,0.00065967336],"category_scores_gemma":[0.0002494604,0.00022868258,0.000059373084,0.0001563704,0.000015401909,0.0001459479,0.000044308148,0.00014708564,0.00006550591],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011189475,0.00025789198,0.061673034,0.00037950263,0.000039277864,0.000121385754,0.00016602401,0.00461005,0.41527134,0.00017954785,0.48038992,0.035793062],"study_design_scores_gemma":[0.002427562,0.00010952422,0.05244626,0.0011143831,0.000049108738,0.000020077005,0.0004367958,0.0036724105,0.7690167,0.0003401176,0.16921318,0.0011539205],"about_ca_topic_score_codex":0.42299038,"about_ca_topic_score_gemma":0.46933487,"teacher_disagreement_score":0.3537453,"about_ca_system_score_codex":0.0010970588,"about_ca_system_score_gemma":0.00055280986,"threshold_uncertainty_score":0.9325405},"labels":[],"label_agreement":null},{"id":"W4233017224","doi":"10.2165/00128413-200213330-00013","title":"Inappropriate pantoprazole use in Canada despite guidelines","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pantoprazole; Pharmacy; Intensive care medicine; Internal medicine; Family medicine; Omeprazole","score_opus":0.22547757895640566,"score_gpt":0.3783929247872928,"score_spread":0.15291534583088714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233017224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96184635,0.0035399732,0.000012702481,0.028834892,0.00043208324,0.0003028509,0.000021872644,0.000041413186,0.004967839],"genre_scores_gemma":[0.9825122,0.0026275653,0.0005255656,0.012642444,0.00023491202,0.000022294713,0.000005264952,0.000020368065,0.001409426],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854296,0.00005533544,0.00041908768,0.000245442,0.00032806993,0.00040910565],"domain_scores_gemma":[0.9991782,0.00019479755,0.00008598144,0.00018660493,0.00013213413,0.00022232083],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002077187,0.0001678058,0.00028995518,0.000056115212,0.00006870543,0.000030003022,0.00010485804,0.000040394785,0.0017089178],"category_scores_gemma":[0.0004604207,0.00013682696,0.000045972214,0.00027864802,0.000032115066,0.00026477367,0.000078979545,0.00033782166,0.00012401625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047432934,0.00037515376,0.47166514,0.00016854856,0.00023875532,0.0023065982,0.00037837596,0.00009831061,0.006128063,0.0000618503,0.364019,0.15408586],"study_design_scores_gemma":[0.0020578005,0.000056964956,0.056686554,0.00006455595,0.000082751074,0.00008227722,0.000177808,0.008557786,0.0014296084,0.000018194443,0.93057036,0.00021535729],"about_ca_topic_score_codex":0.68225163,"about_ca_topic_score_gemma":0.5105882,"teacher_disagreement_score":0.5665513,"about_ca_system_score_codex":0.00026357727,"about_ca_system_score_gemma":0.00015358384,"threshold_uncertainty_score":0.9992037},"labels":[],"label_agreement":null},{"id":"W4233022709","doi":"10.2165/00128413-200615320-00042","title":"Health Canada has warned consumers about counterfeit and unapproved products for avian influenza.","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Counterfeit; Medicine; Influenza A virus subtype H5N1; Pharmacy; Virology; Advertising; Environmental health; Commerce; Business; Family medicine; Virus; Political science; Law","score_opus":0.04094740791769242,"score_gpt":0.2938180971714604,"score_spread":0.252870689253768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233022709","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45140305,0.0021218662,0.00012222528,0.53628576,0.0019019361,0.0018905603,0.0001401933,0.00021384023,0.005920582],"genre_scores_gemma":[0.8125605,0.000027919265,0.0001493496,0.18523276,0.0014377543,0.00008989362,0.00012607577,0.000035674875,0.00034005646],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978484,0.000031458934,0.0006228543,0.00041497016,0.00017002867,0.0009122966],"domain_scores_gemma":[0.998959,0.00010911626,0.00039114835,0.00021602974,0.0002625765,0.000062137675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080126926,0.00024243558,0.00045409106,0.00011133823,0.0004617935,0.0001936951,0.0002004664,0.00007524842,0.00002221835],"category_scores_gemma":[0.00032576686,0.0002269816,0.000038183007,0.00028197232,0.00014123507,0.00042072777,0.00009271165,0.00015304648,0.000021041962],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053525433,0.000029702669,0.009489855,0.0006633446,0.00002113368,0.0000024851724,0.000015633488,0.000102641614,0.00004664098,0.004905809,0.98255056,0.0021186615],"study_design_scores_gemma":[0.001144268,0.000017485434,0.024883768,0.00002921082,0.000017200864,0.0000045693178,0.00008817234,0.0033149521,0.000007187803,0.0004498452,0.96982265,0.00022071636],"about_ca_topic_score_codex":0.93340254,"about_ca_topic_score_gemma":0.40858075,"teacher_disagreement_score":0.5248218,"about_ca_system_score_codex":0.00016715251,"about_ca_system_score_gemma":0.00071259384,"threshold_uncertainty_score":0.9256041},"labels":[],"label_agreement":null},{"id":"W4233820458","doi":"10.2165/00128413-200514910-00055","title":"The Therapeutic Products Directorate of Canada has issued a Notice of Compliance for metformin","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; Medicine; Metformin; Compliance (psychology); Pharmacy; Intensive care medicine; Family medicine; Diabetes mellitus; Law; Political science; Endocrinology","score_opus":0.5281201482468323,"score_gpt":0.44061595759940797,"score_spread":0.08750419064742432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233820458","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45007294,0.04407127,0.004511854,0.48358712,0.0036200483,0.0053236494,0.0022111647,0.000083483836,0.006518451],"genre_scores_gemma":[0.99106145,0.000095565476,0.002587312,0.00367465,0.0003442451,0.00013105906,0.000010745847,0.000029195571,0.002065759],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964289,0.00013734694,0.002655331,0.00030586778,0.00010552301,0.00036701365],"domain_scores_gemma":[0.9956317,0.0014437657,0.0021279936,0.00046681767,0.00024390753,0.000085834414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007393465,0.00014907845,0.00069452124,0.00007908565,0.00023176175,0.00003402151,0.000403498,0.000050573046,0.000071504306],"category_scores_gemma":[0.0017750402,0.00014774673,0.00007547426,0.00020420355,0.00011879819,0.00023962463,0.000028517896,0.000097059215,0.000054469478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007786158,0.0009038134,0.017781563,0.007412255,0.0016058483,0.000002109929,0.010911743,0.0049392213,0.0029711393,0.19654535,0.7315086,0.024639703],"study_design_scores_gemma":[0.001175948,0.00008569533,0.005826553,0.000086731365,0.000019934661,0.000002871305,0.0005096643,0.015206419,0.005144101,0.0021258842,0.9695288,0.00028741328],"about_ca_topic_score_codex":0.038082648,"about_ca_topic_score_gemma":0.04003468,"teacher_disagreement_score":0.5409885,"about_ca_system_score_codex":0.00032945146,"about_ca_system_score_gemma":0.00074197055,"threshold_uncertainty_score":0.9774822},"labels":[],"label_agreement":null},{"id":"W4234132940","doi":"10.2165/00128413-200716130-00053","title":"Biovail has launched a once-daily tramadol formulation [Ralivia] in Canada for the management of moderately severe pain","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Pain Management and Placebo Effect","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tramadol; Medicine; Launched; Pharmacy; Physical therapy; Anesthesia; Family medicine; Analgesic; Engineering","score_opus":0.06399885725976563,"score_gpt":0.27929845342081433,"score_spread":0.2152995961610487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234132940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8668673,0.00014459963,0.12304846,0.0027282713,0.00050073187,0.0033255722,0.000050242794,0.000068917616,0.003265924],"genre_scores_gemma":[0.99763644,0.000029101775,0.00029347074,0.0012734447,0.000042387466,0.000044085737,0.000007694553,0.000018957948,0.0006544318],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980848,0.00039579274,0.0003811721,0.0003099841,0.00038894033,0.0004393016],"domain_scores_gemma":[0.99741614,0.0021316225,0.00012124966,0.00024680656,0.000028103606,0.000056103618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004861038,0.00017890117,0.00018398096,0.00010786668,0.00014986323,0.000052299183,0.00036855135,0.000038908354,0.000041386164],"category_scores_gemma":[0.00018024429,0.00014221028,0.00007275558,0.00044446278,0.000028422075,0.00017737254,0.000053786513,0.00012739642,0.000007395879],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005764823,0.00064125063,0.017484007,0.002772026,0.00041449274,0.00061290286,0.003569315,0.09815605,0.10352714,0.0082069095,0.068534724,0.6903164],"study_design_scores_gemma":[0.0033584693,0.00010374882,0.01691794,0.00013466273,0.00008029409,0.0000037398947,0.0009816546,0.93091094,0.027149733,0.000800777,0.019112399,0.0004456259],"about_ca_topic_score_codex":0.062507845,"about_ca_topic_score_gemma":0.18375674,"teacher_disagreement_score":0.8327549,"about_ca_system_score_codex":0.00023198576,"about_ca_system_score_gemma":0.00012213686,"threshold_uncertainty_score":0.943735},"labels":[],"label_agreement":null},{"id":"W4234456851","doi":"10.2165/00128413-200716160-00066","title":"Health Canada has approved anidulafungin [Eraxis; Pfizer].","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anidulafungin; Pharmacy; Family medicine; Dermatology","score_opus":0.024275278019914956,"score_gpt":0.3019655304416766,"score_spread":0.27769025242176165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234456851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95848453,0.004339843,0.00038077537,0.02642068,0.00089239655,0.0010645149,0.00015121512,0.00019041638,0.00807564],"genre_scores_gemma":[0.9890114,0.000046853907,0.0004210704,0.0077768774,0.0002485663,0.000008093217,0.00011728469,0.00003416731,0.002335652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843043,0.000023365015,0.0003196726,0.00028498037,0.00039311463,0.00054840837],"domain_scores_gemma":[0.9988207,0.000047951595,0.00008934778,0.00028717515,0.000070646856,0.0006841646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016869452,0.00019289863,0.00032222585,0.000074744974,0.00014542394,0.000022463297,0.000085028434,0.00004227416,0.00027264486],"category_scores_gemma":[0.000029689243,0.0001677149,0.00008916717,0.00021505372,0.00003751706,0.000055851477,0.000028595872,0.00015298137,0.000074097545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001262627,0.001464902,0.18594803,0.0003827384,0.0006080571,0.0032907776,0.00028214615,0.0000064156256,0.0025543864,0.00028351747,0.6674344,0.13648202],"study_design_scores_gemma":[0.007952264,0.0005269836,0.46187034,0.000119029726,0.00016844297,0.0001960086,0.00024162118,0.00013414989,0.0036714012,0.000060065508,0.524715,0.0003446735],"about_ca_topic_score_codex":0.37635627,"about_ca_topic_score_gemma":0.20264098,"teacher_disagreement_score":0.27592233,"about_ca_system_score_codex":0.0004977768,"about_ca_system_score_gemma":0.0015370063,"threshold_uncertainty_score":0.8119087},"labels":[],"label_agreement":null},{"id":"W4234589576","doi":"10.2165/00128413-200414430-00058","title":"The dermatology unit of Aventis Pharma has launched a benzoyl peroxide/clindamycin [BenzaClin] topical gel in Canada","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Nail Diseases and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Benzoyl peroxide; Medicine; Dermatology; Pharmacy; Clindamycin; Launched; Family medicine; Organic chemistry; Chemistry; Engineering; Antibiotics","score_opus":0.03369672348768448,"score_gpt":0.30097069412356364,"score_spread":0.26727397063587915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234589576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653466,0.0016452454,0.000010880553,0.01052768,0.0002954227,0.0004105743,0.00004934474,0.00001962071,0.00050659815],"genre_scores_gemma":[0.9981924,0.00017404802,0.00008853713,0.0010722493,0.0000738187,0.000039069557,0.00003315278,0.000021620795,0.00030507115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840826,0.00007150718,0.00052691123,0.00024702764,0.00032957186,0.00041672896],"domain_scores_gemma":[0.999087,0.00015371504,0.00012248778,0.00030042193,0.0000913985,0.00024501025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007822689,0.00019312405,0.0003954285,0.00007366709,0.000109302986,0.000015571242,0.00017585042,0.00006751527,0.0003406392],"category_scores_gemma":[0.000083073486,0.00014012323,0.00012880916,0.00023500144,0.00011681665,0.000057050234,0.00005937534,0.00025485826,0.000046308323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015873604,0.0015848516,0.9588075,0.00027839688,0.0006849146,0.006434867,0.0005151063,0.00010048764,0.003963723,0.00078801217,0.008639838,0.016614906],"study_design_scores_gemma":[0.028668694,0.0003328504,0.88779706,0.00026457975,0.000537815,0.00065998523,0.0010278295,0.0001982208,0.036683433,0.000783888,0.042656463,0.00038916862],"about_ca_topic_score_codex":0.32347864,"about_ca_topic_score_gemma":0.4005993,"teacher_disagreement_score":0.07712068,"about_ca_system_score_codex":0.00035585614,"about_ca_system_score_gemma":0.0021319475,"threshold_uncertainty_score":0.6810264},"labels":[],"label_agreement":null},{"id":"W4235394295","doi":"10.2165/00128413-200313800-00057","title":"Market news from Canada","year":2003,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Advertising; Family medicine; Business","score_opus":0.01773726546594473,"score_gpt":0.27778242356339683,"score_spread":0.2600451580974521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235394295","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12688132,0.00055950496,0.000020713891,0.014421405,0.0015931543,0.00013001032,0.000048664002,0.000041066523,0.85630417],"genre_scores_gemma":[0.9790608,0.00008270302,0.00015458184,0.001138902,0.00038204022,0.000006578204,0.0000027913163,0.000005913799,0.019165643],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991728,0.00013058489,0.000101534024,0.00012230925,0.00025012542,0.00022262378],"domain_scores_gemma":[0.9996094,0.000103802624,0.00003139767,0.000091734415,0.000047605572,0.00011605791],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013002323,0.00006156683,0.00008125727,0.000012782684,0.000565757,0.000035721692,0.000092526214,0.00003022132,0.0041322457],"category_scores_gemma":[0.000115440795,0.000055278975,0.000032297325,0.00015578662,0.00008144347,0.00007878713,0.000014311423,0.00006838338,0.000026622745],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003918699,0.0000146646735,0.008064969,0.0000012280142,0.000027397382,0.000026841832,0.0016947294,0.000004891505,0.000037034457,0.00669035,0.98120725,0.0022267173],"study_design_scores_gemma":[0.00014366282,0.0000028361835,0.007817276,0.0000023904465,0.000009823361,3.588888e-7,0.003432686,0.000004994579,0.00004930448,0.00058423344,0.9878684,0.0000840336],"about_ca_topic_score_codex":0.9572387,"about_ca_topic_score_gemma":0.9715007,"teacher_disagreement_score":0.8521795,"about_ca_system_score_codex":0.00013307596,"about_ca_system_score_gemma":0.00066987803,"threshold_uncertainty_score":0.99677813},"labels":[],"label_agreement":null},{"id":"W4236537247","doi":"10.2165/00128413-200313780-00008","title":"Statin therapy cost saving for prevention of CVD in Canada","year":2003,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Intensive care medicine; Family medicine","score_opus":0.03379908012347198,"score_gpt":0.31107448877685345,"score_spread":0.27727540865338146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236537247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945625,0.0014218376,0.001261184,0.00031104664,0.00016145076,0.0013708924,0.000017398941,0.000007142828,0.0008865275],"genre_scores_gemma":[0.9980907,0.0002141389,0.00094539666,0.00036793563,0.00005264428,0.00011119885,0.000013471813,0.000014488833,0.00019001895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915624,0.00007223721,0.00024379343,0.00012217299,0.0002243456,0.00018121292],"domain_scores_gemma":[0.9996044,0.00003570303,0.00006546158,0.00015624614,0.000069215035,0.00006896937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042736297,0.00007137804,0.00023324185,0.0000437184,0.000021224909,0.0000028272864,0.000033933848,0.000025008985,0.000091659706],"category_scores_gemma":[0.000061271,0.00006337949,0.00008525602,0.00012109294,0.000008822713,0.000033836797,0.000003727245,0.000081612074,0.0000010039712],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006710823,0.0004311844,0.06728333,0.0009397321,0.00034319347,0.000065268345,0.0006048677,0.00013475749,0.03290577,0.00088035857,0.007947645,0.8877928],"study_design_scores_gemma":[0.030238338,0.0010827561,0.3204204,0.00064121134,0.00014432003,0.000100512174,0.002258258,0.0005555141,0.27871913,0.0006453095,0.3646886,0.00050562405],"about_ca_topic_score_codex":0.36345375,"about_ca_topic_score_gemma":0.23098381,"teacher_disagreement_score":0.8872872,"about_ca_system_score_codex":0.00023772837,"about_ca_system_score_gemma":0.0012255345,"threshold_uncertainty_score":0.78304875},"labels":[],"label_agreement":null},{"id":"W4237312607","doi":"10.2165/00128413-200514930-00064","title":"Health Canada has approved a new indication for candesartan cilexetil","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Candesartan; Medicine; Pharmacy; Intensive care medicine; Family medicine; Internal medicine; Angiotensin II; Receptor","score_opus":0.03292257216751831,"score_gpt":0.2989812046243451,"score_spread":0.26605863245682676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237312607","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22742881,0.0025343534,0.0015886064,0.75354254,0.0005655204,0.0024658998,0.000062549756,0.00020425755,0.011607479],"genre_scores_gemma":[0.95862395,0.000057122266,0.001575511,0.024718165,0.0009437452,0.00006171213,0.00010183794,0.000030865474,0.013887098],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877006,0.000036911366,0.00031272136,0.00022718537,0.0003103867,0.00034273096],"domain_scores_gemma":[0.9989757,0.00018705174,0.00010052713,0.00020418981,0.000055982895,0.0004765319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023753835,0.00014378986,0.00050996337,0.000059650323,0.000112663976,0.000024562361,0.00007676255,0.000056188783,0.00013368516],"category_scores_gemma":[0.00009471906,0.00012415754,0.00016948677,0.00013200856,0.000030808307,0.000054009513,0.000009956176,0.00012563399,0.00001861353],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048473748,0.00012609448,0.014801383,0.00014892861,0.00014488338,0.00003572328,0.00067244464,0.000023971099,0.0006114568,0.0011392034,0.7860627,0.19574846],"study_design_scores_gemma":[0.0025582751,0.00010308124,0.025830477,0.000025168632,0.00005189092,0.00007134843,0.00006975823,0.0002426004,0.0006249486,0.00001115649,0.970285,0.00012632096],"about_ca_topic_score_codex":0.18360959,"about_ca_topic_score_gemma":0.21795727,"teacher_disagreement_score":0.73119515,"about_ca_system_score_codex":0.00039687092,"about_ca_system_score_gemma":0.0032970803,"threshold_uncertainty_score":0.8218268},"labels":[],"label_agreement":null},{"id":"W4237317969","doi":"10.2165/00128413-200213670-00047","title":"Market news from Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.0267519930970027,"score_gpt":0.2678704925917876,"score_spread":0.24111849949478487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237317969","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11023319,0.0010655862,0.000008320846,0.057518534,0.0014425169,0.00013528345,0.00007788816,0.00006305167,0.8294556],"genre_scores_gemma":[0.9598615,0.00021074641,0.000070333575,0.0014109752,0.00089008745,0.000006146878,0.0000025656755,0.000005818948,0.037541803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921215,0.00006997543,0.00010304037,0.00012240578,0.00027143842,0.00022097872],"domain_scores_gemma":[0.99962234,0.00009448114,0.00003178871,0.00009425537,0.000041288306,0.00011584408],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000665671,0.000061465405,0.00008131589,0.000013958693,0.0005741772,0.000039365063,0.00012365995,0.000030327987,0.01255289],"category_scores_gemma":[0.000050665327,0.000055262117,0.000033827768,0.00015244991,0.00008855228,0.000093475544,0.000028323588,0.00007191754,0.000075125405],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001796127,0.000012118099,0.0026760306,7.8421147e-7,0.00001683493,0.000022879374,0.0019930343,0.0000025000213,0.00001432989,0.00040684073,0.9877154,0.007137404],"study_design_scores_gemma":[0.00013744392,0.0000033738825,0.008251695,0.000002888696,0.000009964265,3.0621337e-7,0.002051863,0.00010085348,0.000011041367,0.00013833318,0.98920685,0.000085367144],"about_ca_topic_score_codex":0.9656278,"about_ca_topic_score_gemma":0.9684946,"teacher_disagreement_score":0.8496283,"about_ca_system_score_codex":0.00012508506,"about_ca_system_score_gemma":0.0001237904,"threshold_uncertainty_score":0.9883498},"labels":[],"label_agreement":null},{"id":"W4237480749","doi":"10.2165/00128413-200514870-00042","title":"Health Canada has approved pegaptanib","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cardiac, Anesthesia and Surgical Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pegaptanib; Pharmacy; Family medicine; Internal medicine; Bevacizumab; Ranibizumab","score_opus":0.025213595208605114,"score_gpt":0.27756608690151513,"score_spread":0.25235249169291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237480749","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26980117,0.0030003325,0.00012089429,0.643227,0.0006924632,0.0008513134,0.00002793871,0.00024970318,0.08202923],"genre_scores_gemma":[0.9525479,0.00007584487,0.0005819917,0.030723084,0.00066112017,0.00001437983,0.00002399424,0.00002760191,0.015344063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985936,0.000061639235,0.00030671817,0.00022935563,0.0004142735,0.00039438598],"domain_scores_gemma":[0.9990584,0.00014352633,0.00006401033,0.00025065802,0.00005225559,0.0004311247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022767385,0.00016123788,0.0006037931,0.00004596765,0.00010800926,0.00002493614,0.00008455609,0.00004800566,0.00040047622],"category_scores_gemma":[0.000059428196,0.00013310544,0.00019415117,0.00014147902,0.000046678535,0.00005916499,0.000019205672,0.0002074222,0.00010542221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042559113,0.00030744716,0.033211723,0.00019468591,0.00026125976,0.0009266485,0.00059878663,0.000037715217,0.0011112415,0.0020815139,0.8188534,0.14199002],"study_design_scores_gemma":[0.0014388576,0.000061945095,0.03515936,0.000019663219,0.000033679346,0.00030142118,0.00008955604,0.00016304768,0.00037919884,0.000002304695,0.9622164,0.00013457808],"about_ca_topic_score_codex":0.154961,"about_ca_topic_score_gemma":0.12133133,"teacher_disagreement_score":0.68274677,"about_ca_system_score_codex":0.0003186938,"about_ca_system_score_gemma":0.0013128576,"threshold_uncertainty_score":0.8947021},"labels":[],"label_agreement":null},{"id":"W4237810388","doi":"10.2165/00128413-200615410-00053","title":"Health Canada has approved Pfizer's sunitinib for the treatment of gastrointestinal stromal tumour","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; GiST; Pharmacy; Imatinib; Stromal cell; Internal medicine; Oncology; Intensive care medicine; Family medicine; Cancer","score_opus":0.05069886737319331,"score_gpt":0.3131519381821563,"score_spread":0.262453070808963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237810388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509858,0.0011201951,0.0013768029,0.041992348,0.00012531733,0.0029653136,0.0005531216,0.00007036154,0.0008107718],"genre_scores_gemma":[0.9925124,0.000016076545,0.005358858,0.00019299815,0.00031936652,0.00021841344,0.00017213622,0.000033353135,0.0011763761],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9981335,0.000058563455,0.00043027542,0.0002708828,0.0004324222,0.0006743844],"domain_scores_gemma":[0.99860907,0.0004007338,0.0001838352,0.00027625164,0.00022966984,0.00030044248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015622163,0.00025069562,0.00044092254,0.0000657503,0.00022568917,0.000027588403,0.00012845325,0.00001161926,0.000065146945],"category_scores_gemma":[0.0000734459,0.00015939459,0.00017185694,0.00013879151,0.00015631289,0.000031677348,0.00001804034,0.00011961466,0.000004732361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015216601,0.01763531,0.39320996,0.0015463794,0.0012221152,0.004650923,0.00041707067,0.0006612434,0.07135955,0.002029351,0.4323275,0.05972398],"study_design_scores_gemma":[0.040150695,0.055474184,0.7075399,0.00082738075,0.000667866,0.010438641,0.0017193322,0.0055015096,0.04827097,0.00027809077,0.12850663,0.00062475185],"about_ca_topic_score_codex":0.5043595,"about_ca_topic_score_gemma":0.20295665,"teacher_disagreement_score":0.31432998,"about_ca_system_score_codex":0.00057027565,"about_ca_system_score_gemma":0.0022577227,"threshold_uncertainty_score":0.81158733},"labels":[],"label_agreement":null},{"id":"W4238567827","doi":"10.2165/00128413-200514860-00055","title":"Nicotinic acid [niacin] extended-release tablets [Niaspan] have been launched in Canada","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Niacin; Medicine; Launched; Pharmacy; Pharmacology; Nicotinic agonist; Family medicine; Internal medicine; Engineering","score_opus":0.04005818013570484,"score_gpt":0.3366964691176261,"score_spread":0.29663828898192124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238567827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91011786,0.008011794,0.00001757326,0.055117644,0.00047351618,0.0006565043,0.0000645527,0.00008681863,0.025453707],"genre_scores_gemma":[0.98237616,0.0010799996,0.000291667,0.013879342,0.00060398626,0.000048769605,0.000020882177,0.000038517548,0.0016606742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99753946,0.00011857051,0.00055250595,0.00045573158,0.00054634415,0.0007874158],"domain_scores_gemma":[0.99860805,0.00028699386,0.00015286208,0.00031937176,0.000099082754,0.0005336182],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037435026,0.00030762653,0.0005385314,0.00008976052,0.0001193116,0.000028337294,0.00021380326,0.00008514946,0.0027087356],"category_scores_gemma":[0.00030839635,0.00026787847,0.00009535779,0.00028727297,0.000064789645,0.0002831582,0.00014405562,0.0007742103,0.00029444945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032057017,0.0018360752,0.15474662,0.0004645165,0.00087403296,0.0027107303,0.0011301968,0.00026866616,0.055094942,0.00013809251,0.2720662,0.50746423],"study_design_scores_gemma":[0.0059963255,0.0001542362,0.09694763,0.000110064684,0.00027007627,0.00014682712,0.00068527844,0.0032702796,0.022239635,0.000033549382,0.8696689,0.0004771704],"about_ca_topic_score_codex":0.35287035,"about_ca_topic_score_gemma":0.5719416,"teacher_disagreement_score":0.5976027,"about_ca_system_score_codex":0.00079974445,"about_ca_system_score_gemma":0.0009771283,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W4238956926","doi":"10.2165/00128413-200012510-00053","title":"ADR updates from Canada","year":2000,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.23416960925826763,"score_gpt":0.3901204614675273,"score_spread":0.1559508522092597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238956926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8868352,0.002713258,0.00008612282,0.07114873,0.0010644494,0.00034766033,0.0017332991,0.00008841449,0.03598287],"genre_scores_gemma":[0.9444167,0.0001999926,0.00083706464,0.04795674,0.00086848426,0.000058910075,0.00016846364,0.000042578966,0.0054510627],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635,0.00014757056,0.0024513558,0.00051438616,0.00010110461,0.0004355901],"domain_scores_gemma":[0.99809724,0.00049897074,0.0006406666,0.00047494165,0.000030612846,0.00025756864],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025086307,0.00019123165,0.0006583784,0.00009431591,0.00016641931,0.00007624162,0.00037511982,0.00009105522,0.03709112],"category_scores_gemma":[0.0003840685,0.00025646263,0.00007695995,0.00014303855,0.00003913099,0.0003841715,0.000027600863,0.00018015562,0.0117452685],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021519425,0.00006546241,0.046721302,0.000048581467,0.000106253436,0.000010148537,0.0006115989,0.0002346784,0.000010714414,0.004277666,0.9454293,0.0024627761],"study_design_scores_gemma":[0.00071455404,0.000017595452,0.050103076,0.000023459017,0.0000057984603,0.000003236354,0.0002381901,0.0018247031,0.000051587947,0.0058243545,0.94082934,0.0003641133],"about_ca_topic_score_codex":0.75303686,"about_ca_topic_score_gemma":0.1817049,"teacher_disagreement_score":0.571332,"about_ca_system_score_codex":0.0005678444,"about_ca_system_score_gemma":0.00039551704,"threshold_uncertainty_score":0.99998873},"labels":[],"label_agreement":null},{"id":"W4239001268","doi":"10.2165/00128413-200113090-00057","title":"Market news from Canada","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Advertising; Family medicine; Business","score_opus":0.020230963541874824,"score_gpt":0.28726694644531486,"score_spread":0.26703598290344005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239001268","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2992137,0.00046123247,0.000019597484,0.04643136,0.0013274826,0.00012511281,0.000046966034,0.000056817516,0.65231776],"genre_scores_gemma":[0.969204,0.00025717955,0.000068311994,0.0014955052,0.0010818088,0.000006430618,0.0000052808223,0.000005970487,0.027875524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991979,0.00007015377,0.00010453865,0.00012409034,0.00026926855,0.0002340529],"domain_scores_gemma":[0.99961066,0.00009307661,0.00003209422,0.00009361375,0.00004979712,0.00012073682],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009303779,0.00006200515,0.000082578044,0.000014764345,0.0005768953,0.000039309445,0.00012634837,0.00003059873,0.0044704895],"category_scores_gemma":[0.000049365877,0.000055486336,0.000033206827,0.00018573506,0.00008438156,0.00009731181,0.000030875028,0.00006919883,0.000035050616],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010870368,0.000014475489,0.018632445,7.9501626e-7,0.000025149016,0.00007492799,0.0015992213,0.000005396386,0.000030378067,0.0006955842,0.96954376,0.009367026],"study_design_scores_gemma":[0.00014341822,0.0000032746998,0.030736156,0.0000029556013,0.000009798875,7.2378947e-7,0.0028652386,0.000021624412,0.0000086939535,0.00028616525,0.9658397,0.00008228543],"about_ca_topic_score_codex":0.98449755,"about_ca_topic_score_gemma":0.9883373,"teacher_disagreement_score":0.6699903,"about_ca_system_score_codex":0.00014047336,"about_ca_system_score_gemma":0.00043690365,"threshold_uncertainty_score":0.9964396},"labels":[],"label_agreement":null},{"id":"W4239471540","doi":"10.2165/00128413-200816250-00072","title":"Rivastigmine patch [Exelon; Novartis] for treating Alzheimer's disease (AD) is now available for use in Canada.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Rivastigmine; Medicine; Disease; Pharmacy; Donepezil; Psychiatry; Dementia; Internal medicine; Family medicine","score_opus":0.09349327494708429,"score_gpt":0.3079675040132965,"score_spread":0.2144742290662122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239471540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923944,0.0016805609,0.00014194404,0.0027322222,0.00020700884,0.0013857752,0.0013703995,0.000040967356,0.00004670644],"genre_scores_gemma":[0.98892194,0.00018293675,0.0011842474,0.006187354,0.00034223316,0.0005031033,0.00039306688,0.000070969654,0.0022141535],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99826115,0.00003017608,0.00044571995,0.0005136176,0.0002593471,0.00049001357],"domain_scores_gemma":[0.9985046,0.00033799463,0.00010368361,0.00033008764,0.00025228504,0.0004713648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000664517,0.00028344878,0.0004158684,0.000114474926,0.00016870518,0.000022670263,0.00009914946,0.000037352907,0.0002662511],"category_scores_gemma":[0.00022932398,0.0002652128,0.0001558296,0.00023695992,0.000046164394,0.00023957354,0.000031044296,0.00010924411,0.000026109377],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030349279,0.00061772054,0.4480956,0.00020509608,0.00016828816,0.00080822594,0.00020148214,0.000052675463,0.0167387,0.0000029695927,0.52786446,0.0022098857],"study_design_scores_gemma":[0.033335295,0.00079022406,0.3468673,0.0006463062,0.0019662092,0.00019749143,0.00018510145,0.05566037,0.3204963,0.000031104188,0.2381215,0.0017028266],"about_ca_topic_score_codex":0.08365882,"about_ca_topic_score_gemma":0.14229846,"teacher_disagreement_score":0.3037576,"about_ca_system_score_codex":0.00015036027,"about_ca_system_score_gemma":0.0016148167,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W4239531242","doi":"10.2165/00128413-200414290-00064","title":"The Therapeutic Products Directorate of Health Canada has approved gemifloxacin","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gemifloxacin; Medicine; Pharmacy; Environmental health; Family medicine; Moxifloxacin; Microbiology; Antibiotics","score_opus":0.39394233230825226,"score_gpt":0.4025350128563726,"score_spread":0.008592680548120346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239531242","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25297162,0.02615197,0.0014296803,0.7121821,0.0027453576,0.0018325696,0.00037623537,0.00008796182,0.0022224966],"genre_scores_gemma":[0.9831215,0.00025856314,0.00044359508,0.015161358,0.0002554436,0.00008773315,0.00001876813,0.000037684564,0.00061534223],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99513876,0.00035514554,0.0033787577,0.00045227286,0.0001423623,0.00053270947],"domain_scores_gemma":[0.99620175,0.00047603526,0.0024302173,0.00062917615,0.00011416301,0.00014868102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011266803,0.00019721425,0.000819628,0.00010051466,0.00047410172,0.00008241181,0.00042899992,0.000057701505,0.000052798936],"category_scores_gemma":[0.001103723,0.00019357502,0.00006902656,0.0003069881,0.00013442282,0.00022141376,0.000043309756,0.00019973493,0.00020402134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016931356,0.0007658112,0.030638311,0.0029873631,0.0010217965,0.000007518165,0.012739079,0.005083398,0.00064983114,0.25230753,0.6790197,0.014610342],"study_design_scores_gemma":[0.0019391123,0.00013754604,0.03021706,0.00010440729,0.00000918101,0.000007466552,0.0012616134,0.0007201102,0.0007590903,0.015408922,0.9489218,0.00051367155],"about_ca_topic_score_codex":0.42414302,"about_ca_topic_score_gemma":0.15501617,"teacher_disagreement_score":0.7301499,"about_ca_system_score_codex":0.001157162,"about_ca_system_score_gemma":0.0028574653,"threshold_uncertainty_score":0.8604026},"labels":[],"label_agreement":null},{"id":"W4239662282","doi":"10.2165/00128413-200716170-00054","title":"Product approvals in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Product (mathematics); Pharmacy; Family medicine","score_opus":0.3321649356588049,"score_gpt":0.42406658912105033,"score_spread":0.09190165346224544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239662282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92475915,0.0025194483,0.00089074677,0.04363343,0.0018017349,0.00088171655,0.00013411738,0.000050442104,0.025329225],"genre_scores_gemma":[0.9835208,0.000033248318,0.0009784997,0.0138506945,0.0004959002,0.00004341995,0.0000155878,0.00003032805,0.0010315349],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952229,0.0001178308,0.0034027388,0.00053715694,0.0001093284,0.0006100148],"domain_scores_gemma":[0.9978288,0.0005084057,0.000994819,0.00042177073,0.000040514,0.00020573255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016404832,0.00016780396,0.0006642546,0.000308317,0.00007595725,0.000032429918,0.00030654253,0.000054836146,0.00061160926],"category_scores_gemma":[0.0015253284,0.00022740483,0.000052763047,0.00032581203,0.000029877328,0.00032238886,0.000042070184,0.00022757052,0.0012192426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043096323,0.00015650404,0.70667654,0.00040247547,0.000063647334,0.000042611864,0.001600654,0.000403295,0.000062279854,0.02634399,0.2609862,0.003218716],"study_design_scores_gemma":[0.0016099374,0.000033726334,0.47036248,0.00006401195,0.0000039382444,0.000020016874,0.001793831,0.0017209707,0.00034342916,0.0048276135,0.51849794,0.0007221243],"about_ca_topic_score_codex":0.8150342,"about_ca_topic_score_gemma":0.7832496,"teacher_disagreement_score":0.2575117,"about_ca_system_score_codex":0.002128053,"about_ca_system_score_gemma":0.0009342765,"threshold_uncertainty_score":0.99955845},"labels":[],"label_agreement":null},{"id":"W4239700607","doi":"10.2165/00128413-200816490-00061","title":"Idebenone approved in Canada, but EU needs more data","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Idebenone; Family medicine; Pharmacology","score_opus":0.5159014374493767,"score_gpt":0.4176488603409993,"score_spread":0.09825257710837737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239700607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8864377,0.0029538197,0.0009460925,0.095438294,0.0012980956,0.00084894785,0.0021600486,0.000070636015,0.00984638],"genre_scores_gemma":[0.9667018,0.00023180035,0.00087672484,0.029458528,0.00045677277,0.00006901443,0.00026937632,0.00005215325,0.0018838336],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99501204,0.0001783308,0.0033752734,0.0006681233,0.00015218697,0.0006140575],"domain_scores_gemma":[0.9968176,0.00051452144,0.0010939193,0.001250489,0.000045243873,0.00027821655],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005158581,0.00024137711,0.0009487452,0.0004234714,0.00016912089,0.000035660854,0.0010003855,0.00010560944,0.00066305365],"category_scores_gemma":[0.0013725704,0.00032914846,0.000051790972,0.00043571266,0.000077733006,0.00076551485,0.00022500538,0.00031675518,0.0011936382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036451893,0.00016725996,0.23938525,0.00025281362,0.00010068837,0.000066423134,0.002718995,0.0006225645,0.000034347795,0.0049747378,0.75121194,0.00042852227],"study_design_scores_gemma":[0.0034518442,0.000047284128,0.2699639,0.000083811305,0.000011297429,0.00009301169,0.0053670695,0.07711944,0.00004283577,0.0009983988,0.64166427,0.001156876],"about_ca_topic_score_codex":0.87342286,"about_ca_topic_score_gemma":0.5139825,"teacher_disagreement_score":0.35944036,"about_ca_system_score_codex":0.0014029262,"about_ca_system_score_gemma":0.0017382161,"threshold_uncertainty_score":0.9999161},"labels":[],"label_agreement":null},{"id":"W4240112120","doi":"10.2165/00128413-200615420-00058","title":"Health Canada is warning against the use of the Triaminic Vapour Patch, which contains camphor, eucalyptus oil and menthol,","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Drug-Induced Hepatotoxicity and Protection","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Menthol; Camphor; Medicine; Eucalyptus oil; Eucalyptus; Pharmacy; Traditional medicine; Environmental health; Toxicology; Botany; Organic chemistry; Family medicine; Biology; Chemistry","score_opus":0.13088043866062968,"score_gpt":0.3714705709660939,"score_spread":0.24059013230546425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240112120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96122944,0.0009956034,0.000024371984,0.03379128,0.0018505352,0.00046973382,0.00030183487,0.000049682105,0.0012875022],"genre_scores_gemma":[0.97781944,0.000799648,0.000028435736,0.018576453,0.00030346276,0.00007533656,0.00002038171,0.000030465133,0.002346375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648947,0.001546575,0.0006699014,0.0003578679,0.00034034866,0.00059583917],"domain_scores_gemma":[0.9980461,0.0007688885,0.00050574366,0.00032734335,0.0001669314,0.00018497925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011739129,0.0002984962,0.00041159254,0.00006741342,0.0009972854,0.00004907115,0.00034699004,0.00024456135,0.00011432033],"category_scores_gemma":[0.00014793538,0.00020711382,0.00010540337,0.00046139746,0.00019874658,0.00016401257,0.00014584037,0.0013360473,0.000008834548],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012558796,0.0010625547,0.09715383,0.0006508197,0.0009655948,0.0000736683,0.008453926,0.0064805434,0.07233119,0.0007829038,0.40276676,0.4080223],"study_design_scores_gemma":[0.0029853138,0.00008633152,0.017030021,0.000062363746,0.0001395849,0.00003646643,0.00037734222,0.0071555446,0.03109847,0.00008758133,0.9405919,0.00034908118],"about_ca_topic_score_codex":0.3673585,"about_ca_topic_score_gemma":0.34519154,"teacher_disagreement_score":0.5378251,"about_ca_system_score_codex":0.0003241299,"about_ca_system_score_gemma":0.0010931339,"threshold_uncertainty_score":0.84458566},"labels":[],"label_agreement":null},{"id":"W4240272195","doi":"10.2165/00128413-200213470-00011","title":"IV heparin use higher among US vs Canadian neurologists","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Heparin; Family medicine; Internal medicine","score_opus":0.04457635898650299,"score_gpt":0.25686082834952967,"score_spread":0.2122844693630267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240272195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483326,0.00020327004,0.00000278746,0.011531222,0.0008063853,0.0005175541,0.000014900878,0.00014975635,0.038441505],"genre_scores_gemma":[0.9706847,0.00031874355,0.00007285793,0.019490568,0.0003441392,0.000059434635,0.000017155444,0.00004596214,0.008966448],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998435,0.000050563413,0.0002646484,0.00037809383,0.000258943,0.00061274617],"domain_scores_gemma":[0.99879295,0.00004102176,0.000065297514,0.00044208518,0.00006109146,0.0005975604],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010851992,0.00022104921,0.00038914377,0.00021964486,0.0001275273,0.00008356715,0.00017473513,0.00010865813,0.0054456615],"category_scores_gemma":[0.00004636582,0.00020638337,0.00011095405,0.00022338568,0.00009963719,0.00019995615,0.00006803966,0.0002707684,0.0011320062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003087253,0.00044097792,0.41307697,0.000049500162,0.00014835938,0.001682427,0.00016744083,0.00004552301,0.0001916018,0.00040506403,0.5802174,0.003543829],"study_design_scores_gemma":[0.0006425087,0.00015358602,0.6126273,0.000017197792,0.0001029375,0.000013783259,0.0000033193637,0.00040793122,0.00007181157,0.000009948517,0.38581467,0.00013497383],"about_ca_topic_score_codex":0.18920964,"about_ca_topic_score_gemma":0.04192494,"teacher_disagreement_score":0.19955035,"about_ca_system_score_codex":0.00014037335,"about_ca_system_score_gemma":0.000037407506,"threshold_uncertainty_score":0.9996457},"labels":[],"label_agreement":null},{"id":"W4241129018","doi":"10.2165/00128413-200012260-00049","title":"Ropinirole: sudden onset of sleep warning issued in Canada","year":2000,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Sleep and related disorders","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ropinirole; Medicine; Sleep (system call); Pharmacy; Psychiatry; Internal medicine; Family medicine; Agonist","score_opus":0.009307827362471868,"score_gpt":0.2671578414079682,"score_spread":0.25785001404549635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241129018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9370669,0.0013600287,0.0000030805425,0.000985113,0.00067597145,0.00014523523,0.000020017525,0.00002913113,0.059714533],"genre_scores_gemma":[0.9959239,0.00009517502,0.00001975393,0.00064423843,0.000048228365,0.000017047047,0.000019065268,0.000024350313,0.0032082526],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986766,0.00013417403,0.0003717535,0.00024706335,0.00018249088,0.0003879012],"domain_scores_gemma":[0.9994664,0.00009345209,0.00007508253,0.00024941587,0.000021950958,0.00009364965],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011503994,0.0001449719,0.00023217012,0.00010908002,0.000035447774,0.0000053899325,0.00023508127,0.000108626075,0.023960482],"category_scores_gemma":[0.000014232986,0.00014240948,0.00004702398,0.00033089827,0.000046217192,0.00004807557,0.000016654969,0.00031838752,0.00042184358],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009205224,0.00077346,0.2733407,0.000048034006,0.00094825344,0.0014197682,0.010613119,0.0039326786,0.00054797804,0.00013730116,0.2326297,0.47468847],"study_design_scores_gemma":[0.020778533,0.0003767725,0.48391593,0.00021779058,0.00032273456,0.00027467342,0.013298677,0.0031988958,0.0019516926,0.00033185922,0.4736862,0.0016462618],"about_ca_topic_score_codex":0.8287892,"about_ca_topic_score_gemma":0.36918962,"teacher_disagreement_score":0.47304222,"about_ca_system_score_codex":0.000087640714,"about_ca_system_score_gemma":0.00020778664,"threshold_uncertainty_score":0.97693175},"labels":[],"label_agreement":null},{"id":"W4241365950","doi":"10.2165/00128413-200514760-00056","title":"Ethinylestradiol/drospirenone [Yasmin; Berlex Canada] has been launched in Canada,","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drospirenone; Medicine; Launched; Ethinylestradiol; Gynecology; Environmental health; Population; Research methodology; Engineering","score_opus":0.030514620886917497,"score_gpt":0.2804845569241142,"score_spread":0.24996993603719672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241365950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93535095,0.0011468044,0.0000019242093,0.056566764,0.00071074074,0.00043184933,0.000098502,0.00003896199,0.0056535075],"genre_scores_gemma":[0.982596,0.00008697782,0.0001531573,0.010873864,0.00081543834,0.000058990852,0.00008416009,0.000036165697,0.005295294],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815553,0.00005890491,0.0004224082,0.00036040615,0.00041859594,0.0005841615],"domain_scores_gemma":[0.9990868,0.00010725849,0.00009019106,0.00023872254,0.00008538484,0.00039165354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001362966,0.00026863156,0.00047058682,0.000094391726,0.00008444153,0.000015037968,0.0001632387,0.00008766845,0.0018511267],"category_scores_gemma":[0.000028153889,0.0002630265,0.0000591087,0.00026995613,0.00006532647,0.00008821159,0.00003469782,0.00047542018,0.00002968547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003704105,0.00036044384,0.13396145,0.000073470546,0.0002559107,0.0022927064,0.0005083901,0.0002310995,0.008999346,0.0000155844,0.81240946,0.04052172],"study_design_scores_gemma":[0.0077191163,0.0001769227,0.27438846,0.000056517703,0.00021782298,0.00016971152,0.0001863496,0.0007204184,0.014648989,0.000009280721,0.7013137,0.00039274053],"about_ca_topic_score_codex":0.9985098,"about_ca_topic_score_gemma":0.9998623,"teacher_disagreement_score":0.140427,"about_ca_system_score_codex":0.0035206205,"about_ca_system_score_gemma":0.011440113,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W4241551250","doi":"10.2165/00128413-200816220-00084","title":"Frovatriptan [Frova; Teva Neuroscience Canada] has been launched in Canada for the treatment of migraines with or without aura in adults.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Aura; Medicine; Pharmacy; Launched; Family medicine; Psychiatry; Migraine; Engineering","score_opus":0.05994279408294232,"score_gpt":0.2833808924903209,"score_spread":0.22343809840737858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241551250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868817,0.0011333731,0.000008688678,0.010547214,0.000066289234,0.0011356163,0.00008061239,0.000009849534,0.00013665833],"genre_scores_gemma":[0.995248,0.00058406865,0.0001514863,0.0013687958,0.00009794419,0.00008874976,0.000009236674,0.000019623998,0.0024320874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985122,0.000026239983,0.00038586,0.0002993395,0.00037829462,0.0003980694],"domain_scores_gemma":[0.9991938,0.00021375241,0.00010827484,0.0002546046,0.00012362566,0.00010595786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009121386,0.00022125345,0.0005233143,0.000091361435,0.00013271747,0.0000047213252,0.00014776883,0.000026598911,0.000023784274],"category_scores_gemma":[0.00011725892,0.0001189372,0.000048977454,0.0004960192,0.00016320261,0.000044215172,0.000016535101,0.00011269868,2.4389092e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002653133,0.00029455416,0.91919917,0.00017464411,0.00007292361,0.00053999695,0.006706959,0.00004466913,0.00073035137,0.0000036804831,0.06822935,0.001350573],"study_design_scores_gemma":[0.012704942,0.0019607644,0.8084772,0.00023142953,0.00013341983,0.00015038847,0.008682086,0.0028148452,0.0032717038,0.0000029976175,0.1612511,0.0003191111],"about_ca_topic_score_codex":0.99766594,"about_ca_topic_score_gemma":0.9998912,"teacher_disagreement_score":0.11072196,"about_ca_system_score_codex":0.00056997774,"about_ca_system_score_gemma":0.006396884,"threshold_uncertainty_score":0.9992359},"labels":[],"label_agreement":null},{"id":"W4241767819","doi":"10.2165/00128413-200313980-00049","title":"Health Canada has approved a new formulation of methylphenidate ['Concerta'; Janssen-Ortho Inc.] for use in children with ADHD","year":2003,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylphenidate; Medicine; Pharmacy; Psychiatry; Family medicine; Pediatrics; Attention deficit hyperactivity disorder","score_opus":0.07703450529964993,"score_gpt":0.3326952086648549,"score_spread":0.25566070336520497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241767819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878411,0.00020203697,0.005658822,0.0042871283,0.000060769555,0.0017362616,0.000063584055,0.000027925425,0.00012237228],"genre_scores_gemma":[0.9918341,0.000013047525,0.0062222253,0.0011328817,0.00003912986,0.00005011753,0.00018352144,0.00004389941,0.00048106755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844706,0.00008887464,0.00046379943,0.00031919708,0.00033124042,0.00034984853],"domain_scores_gemma":[0.9989656,0.00012336961,0.000283984,0.00027686686,0.00015068369,0.00019945906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024601817,0.00020119222,0.0004893931,0.00014170878,0.00006596375,0.000020443578,0.00006832625,0.00008432485,0.00006674472],"category_scores_gemma":[0.00017489602,0.00018039631,0.00006021894,0.00034545726,0.00003202002,0.0003070662,0.000012813259,0.00025754096,0.0000021306687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013004495,0.00072612625,0.95371246,0.0002832934,0.00049937423,0.000011833996,0.0012510119,0.0012903549,0.005249049,0.0005262776,0.015202025,0.019947758],"study_design_scores_gemma":[0.042945966,0.0015925639,0.85251826,0.00042496662,0.0004915995,0.00035770686,0.002810603,0.0059326603,0.007824529,0.00017184016,0.08381267,0.0011166047],"about_ca_topic_score_codex":0.4388747,"about_ca_topic_score_gemma":0.4194895,"teacher_disagreement_score":0.10119416,"about_ca_system_score_codex":0.00020530893,"about_ca_system_score_gemma":0.002634761,"threshold_uncertainty_score":0.7356348},"labels":[],"label_agreement":null},{"id":"W4242075173","doi":"10.2165/00128413-200816600-00068","title":"Idebenone launched in Canada.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Coenzyme Q10 studies and effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Launched; Medicine; Idebenone; Optometry; Internal medicine; Engineering","score_opus":0.009847695806205469,"score_gpt":0.21519171013862048,"score_spread":0.205344014332415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242075173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637306,0.0012494206,0.000018497609,0.00064093986,0.00020189413,0.00009595089,0.000009169521,0.0000059429212,0.0014051306],"genre_scores_gemma":[0.9977431,0.00034350707,0.000042938078,0.00092574523,0.0001943967,0.000017696275,0.00002126072,0.000012570968,0.00069875637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928766,0.0000275681,0.00013034986,0.00020049163,0.00010486231,0.00024904785],"domain_scores_gemma":[0.9997048,0.000010942966,0.000026879921,0.00016335204,0.000028179373,0.00006586712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005581074,0.00010645532,0.00011997597,0.000020184025,0.000060402377,0.0000029697164,0.00011148534,0.000036543166,0.000042069267],"category_scores_gemma":[0.00003437538,0.00010384923,0.000031007337,0.00009050279,0.000027212434,0.0000016073594,0.000087014945,0.000072819144,0.00001417394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009209553,0.000047128557,0.054653604,0.000014197392,0.000038281592,0.00021313915,0.00007287459,0.000108825014,0.23145954,0.000007690686,0.71252525,0.00076736807],"study_design_scores_gemma":[0.0024664858,0.00019908542,0.25105634,0.00001838922,0.000012717481,0.00014600038,0.00022617057,0.00022228262,0.21410134,0.000009977758,0.5309913,0.00054989976],"about_ca_topic_score_codex":0.37733483,"about_ca_topic_score_gemma":0.72613907,"teacher_disagreement_score":0.34880424,"about_ca_system_score_codex":0.00006243473,"about_ca_system_score_gemma":0.00039585095,"threshold_uncertainty_score":0.62681156},"labels":[],"label_agreement":null},{"id":"W4242890853","doi":"10.2165/00128413-200716110-00060","title":"Product approvals in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Product (mathematics); Mathematics; Geometry","score_opus":0.3321649356588049,"score_gpt":0.42406658912105033,"score_spread":0.09190165346224544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242890853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92475915,0.0025194483,0.00089074677,0.04363343,0.0018017349,0.00088171655,0.00013411738,0.000050442104,0.025329225],"genre_scores_gemma":[0.9835208,0.000033248318,0.0009784997,0.0138506945,0.0004959002,0.00004341995,0.0000155878,0.00003032805,0.0010315349],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952229,0.0001178308,0.0034027388,0.00053715694,0.0001093284,0.0006100148],"domain_scores_gemma":[0.9978288,0.0005084057,0.000994819,0.00042177073,0.000040514,0.00020573255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016404832,0.00016780396,0.0006642546,0.000308317,0.00007595725,0.000032429918,0.00030654253,0.000054836146,0.00061160926],"category_scores_gemma":[0.0015253284,0.00022740483,0.000052763047,0.00032581203,0.000029877328,0.00032238886,0.000042070184,0.00022757052,0.0012192426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043096323,0.00015650404,0.70667654,0.00040247547,0.000063647334,0.000042611864,0.001600654,0.000403295,0.000062279854,0.02634399,0.2609862,0.003218716],"study_design_scores_gemma":[0.0016099374,0.000033726334,0.47036248,0.00006401195,0.0000039382444,0.000020016874,0.001793831,0.0017209707,0.00034342916,0.0048276135,0.51849794,0.0007221243],"about_ca_topic_score_codex":0.8150342,"about_ca_topic_score_gemma":0.7832496,"teacher_disagreement_score":0.2575117,"about_ca_system_score_codex":0.002128053,"about_ca_system_score_gemma":0.0009342765,"threshold_uncertainty_score":0.99955845},"labels":[],"label_agreement":null},{"id":"W4243106559","doi":"10.2165/00128413-200213420-00051","title":"Recent product news from Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Human auditory perception and evaluation","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Product (mathematics); Family medicine","score_opus":0.04848438165908087,"score_gpt":0.24438120378044342,"score_spread":0.19589682212136256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243106559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581704,0.0011900684,0.000072109426,0.002855332,0.004680799,0.00019005273,0.000033766504,0.00040381734,0.032403614],"genre_scores_gemma":[0.9934184,0.00084573147,0.000116404495,0.0007376085,0.0016462234,0.000017379638,0.000036104593,0.000029659714,0.0031525067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99935454,0.00002302966,0.00014582177,0.00012735113,0.00019984673,0.00014939903],"domain_scores_gemma":[0.9997046,0.000010967297,0.00001526958,0.00015904094,0.000030554078,0.00007958001],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000040505125,0.00009364828,0.00007994771,0.000027002921,0.000042182695,0.000022070722,0.00008480444,0.000021591553,0.116865024],"category_scores_gemma":[0.000016218104,0.00009932613,0.000016565351,0.000079492864,0.000008301857,0.00008736968,0.0000077126615,0.00010969078,0.0056536524],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000010088974,0.00000803576,0.00018278982,0.0000041489798,0.000010850845,0.0000034892832,0.00021119881,0.0027242617,0.0068270974,2.3359912e-7,0.8944014,0.0956255],"study_design_scores_gemma":[0.00022568309,0.00000411375,0.008427879,0.0000052111027,0.00000857517,0.0000012136439,0.00004995099,0.021207131,0.0016059479,0.000010252463,0.96831524,0.00013877444],"about_ca_topic_score_codex":0.0073009967,"about_ca_topic_score_gemma":0.10371604,"teacher_disagreement_score":0.111211374,"about_ca_system_score_codex":0.00020352291,"about_ca_system_score_gemma":0.000022759128,"threshold_uncertainty_score":0.9993095},"labels":[],"label_agreement":null},{"id":"W4243495076","doi":"10.1007/bf03294092","title":"Ranibizumab launched for wet AMD in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Launched; Medicine; Ranibizumab; Pharmacy; Optometry; Family medicine; Internal medicine; Engineering","score_opus":0.023996872037995158,"score_gpt":0.29786394733083654,"score_spread":0.2738670752928414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243495076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563684,0.0047149286,0.0066294014,0.011806082,0.005128769,0.0013504412,0.00034455396,0.000113414775,0.013544015],"genre_scores_gemma":[0.9939723,0.00001882544,0.001285893,0.00248157,0.00005182563,0.000012258147,0.000022388134,0.000013275153,0.002141666],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988143,0.00007758897,0.00032927244,0.00023877466,0.00003412545,0.00050597277],"domain_scores_gemma":[0.9992922,0.00040868038,0.000057196463,0.00015195717,0.000048231617,0.000041720203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006871261,0.00013844698,0.00025956778,0.00007054822,0.000059491133,0.0000059902977,0.00018916784,0.00015710013,0.0007830871],"category_scores_gemma":[0.000119424025,0.00011671745,0.00006804072,0.00016467605,0.00006699482,0.000033615648,0.00003601076,0.00024874142,0.00003184923],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022566393,0.0002966361,0.026746215,0.00009098788,0.0003068502,0.00012823123,0.00019268296,0.0000035193368,0.5886529,0.0018712331,0.23068418,0.14876993],"study_design_scores_gemma":[0.0046298183,0.00012917996,0.038184788,0.000023326238,0.0000505014,0.00003743777,0.00033312995,0.000037615366,0.3192799,0.00045002773,0.6365044,0.00033987442],"about_ca_topic_score_codex":0.23057891,"about_ca_topic_score_gemma":0.63213414,"teacher_disagreement_score":0.40582022,"about_ca_system_score_codex":0.00021381491,"about_ca_system_score_gemma":0.0003296029,"threshold_uncertainty_score":0.85742545},"labels":[],"label_agreement":null},{"id":"W4243923408","doi":"10.2165/00128413-200113150-00052","title":"Market news from Canada","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.020230963541874824,"score_gpt":0.28726694644531486,"score_spread":0.26703598290344005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243923408","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2992137,0.00046123247,0.000019597484,0.04643136,0.0013274826,0.00012511281,0.000046966034,0.000056817516,0.65231776],"genre_scores_gemma":[0.969204,0.00025717955,0.000068311994,0.0014955052,0.0010818088,0.000006430618,0.0000052808223,0.000005970487,0.027875524],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991979,0.00007015377,0.00010453865,0.00012409034,0.00026926855,0.0002340529],"domain_scores_gemma":[0.99961066,0.00009307661,0.00003209422,0.00009361375,0.00004979712,0.00012073682],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009303779,0.00006200515,0.000082578044,0.000014764345,0.0005768953,0.000039309445,0.00012634837,0.00003059873,0.0044704895],"category_scores_gemma":[0.000049365877,0.000055486336,0.000033206827,0.00018573506,0.00008438156,0.00009731181,0.000030875028,0.00006919883,0.000035050616],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010870368,0.000014475489,0.018632445,7.9501626e-7,0.000025149016,0.00007492799,0.0015992213,0.000005396386,0.000030378067,0.0006955842,0.96954376,0.009367026],"study_design_scores_gemma":[0.00014341822,0.0000032746998,0.030736156,0.0000029556013,0.000009798875,7.2378947e-7,0.0028652386,0.000021624412,0.0000086939535,0.00028616525,0.9658397,0.00008228543],"about_ca_topic_score_codex":0.98449755,"about_ca_topic_score_gemma":0.9883373,"teacher_disagreement_score":0.6699903,"about_ca_system_score_codex":0.00014047336,"about_ca_system_score_gemma":0.00043690365,"threshold_uncertainty_score":0.9964396},"labels":[],"label_agreement":null},{"id":"W4244309416","doi":"10.2165/00128413-200615400-00068","title":"Auxilium Pharmaceuticals has received marketing approval from Health Canada for its topical testosterone gel","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Immunotoxicology and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Drug approval; Family medicine; Pharmacology; Marketing; Drug; Business","score_opus":0.03935785095437948,"score_gpt":0.28920820495207183,"score_spread":0.24985035399769234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244309416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486101,0.024315765,0.0002554689,0.021184549,0.003201011,0.0011462615,0.00048036093,0.00015644987,0.00064999925],"genre_scores_gemma":[0.98573667,0.00008849293,0.00032592958,0.0036643199,0.00024888455,0.000081604594,0.0005321155,0.000041082945,0.009280905],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968388,0.0009312681,0.00071415736,0.0005139088,0.00007268122,0.0009291529],"domain_scores_gemma":[0.9976017,0.0016748732,0.00023440903,0.00030044504,0.00013062575,0.000057988913],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007460424,0.0003303664,0.00056673837,0.00008236927,0.0007283971,0.00003824857,0.0004027442,0.00030717062,0.0010300555],"category_scores_gemma":[0.0004467545,0.0003204296,0.00012814406,0.00012004419,0.00026825804,0.00011973306,0.00012710674,0.000569345,0.00013771107],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003280205,0.0002877776,0.00091718417,0.000061013983,0.0002539948,0.000021008527,0.00010579077,0.000007507476,0.76451963,0.0000882474,0.21814302,0.012314618],"study_design_scores_gemma":[0.004616654,0.00023889146,0.026457114,0.00005151285,0.000067894194,0.000073387426,0.00017276897,0.00006355466,0.28303996,0.000058504782,0.6847754,0.00038436748],"about_ca_topic_score_codex":0.0648453,"about_ca_topic_score_gemma":0.022957906,"teacher_disagreement_score":0.48147967,"about_ca_system_score_codex":0.00023547749,"about_ca_system_score_gemma":0.0014749866,"threshold_uncertainty_score":0.9999248},"labels":[],"label_agreement":null},{"id":"W4244333022","doi":"10.2165/00128413-200514710-00050","title":"Berlex has announced the Canadian approval of ethinylestradiol/drospirenone","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ethinylestradiol; Drospirenone; Pharmacy; Family medicine; Gynecology; Environmental health; Research methodology","score_opus":0.03238519109358545,"score_gpt":0.27179847325357454,"score_spread":0.23941328215998908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244333022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9731836,0.00037593243,0.000015373376,0.015127038,0.0005892803,0.0005872879,0.000028471653,0.00006059111,0.010032431],"genre_scores_gemma":[0.994747,0.00001688673,0.00030040214,0.0025206902,0.0013175998,0.000030650812,0.00002292921,0.00003014351,0.0010137208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985411,0.00007580544,0.00033598143,0.00021298314,0.0004040745,0.00043003616],"domain_scores_gemma":[0.9988451,0.0000835882,0.00010706861,0.00038060316,0.000190721,0.00039294836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006687121,0.00018811293,0.0003172759,0.00012715273,0.00024166955,0.000030218518,0.00019709207,0.00015352234,0.00023658834],"category_scores_gemma":[0.00015007799,0.0001317585,0.00012488641,0.00023261209,0.00030405988,0.000096856624,0.000020586323,0.00046637442,0.00015250347],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074976485,0.0007348792,0.063434385,0.00091319723,0.00082241814,0.0012409473,0.014047488,0.00042698445,0.16562097,0.0017848064,0.5399999,0.21022427],"study_design_scores_gemma":[0.0046718162,0.00054733764,0.1095221,0.00018688444,0.0002994218,0.0003735091,0.00027397633,0.0030150772,0.065480076,0.00006260375,0.8150752,0.0004919567],"about_ca_topic_score_codex":0.01438539,"about_ca_topic_score_gemma":0.028700242,"teacher_disagreement_score":0.27507535,"about_ca_system_score_codex":0.00018544211,"about_ca_system_score_gemma":0.0010204917,"threshold_uncertainty_score":0.9921779},"labels":[],"label_agreement":null},{"id":"W4244553985","doi":"10.2165/00128413-200715720-00069","title":"Cangene Corporation's hepatitis B immune globulin [HepaGam] has been granted a Notice of Compliance with condition by Health Canada,","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Notice; Medicine; Hepatitis B immune globulin; Compliance (psychology); Corporation; Pharmacy; Family medicine; Immunology; Chronic hepatitis; Law; Political science; Social psychology","score_opus":0.037273384110760886,"score_gpt":0.30001617534630176,"score_spread":0.2627427912355409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244553985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97099304,0.003664134,0.0046450202,0.01584286,0.00042274277,0.0013672797,0.00153641,0.00011378361,0.0014147434],"genre_scores_gemma":[0.99390054,0.00029456717,0.0013727535,0.0031183849,0.00010938051,0.000028608469,0.0005541795,0.000039934446,0.00058167893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776965,0.00007486522,0.0007060804,0.00031215293,0.0006555497,0.00048171307],"domain_scores_gemma":[0.9982662,0.00012466616,0.00049976003,0.0002878577,0.0005558745,0.0002655976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003977528,0.00024912757,0.00064885686,0.000094455,0.0002553688,0.000015252646,0.00012047866,0.000062832114,0.0001333248],"category_scores_gemma":[0.00008530083,0.00023527043,0.000048694597,0.00045814968,0.0002612658,0.00012200436,0.000033733366,0.0002339655,0.00001840217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015018403,0.00064921845,0.5780791,0.0011747204,0.00079448987,0.0007961679,0.0014210102,0.000030415269,0.045514222,0.00016822485,0.35811067,0.011759926],"study_design_scores_gemma":[0.004765515,0.0011767829,0.8968138,0.0008642647,0.00018001653,0.00014847299,0.00018001688,0.00035827348,0.042450577,0.000015920084,0.052620605,0.00042574792],"about_ca_topic_score_codex":0.93062186,"about_ca_topic_score_gemma":0.95095795,"teacher_disagreement_score":0.3187347,"about_ca_system_score_codex":0.0006246551,"about_ca_system_score_gemma":0.0012623828,"threshold_uncertainty_score":0.959405},"labels":[],"label_agreement":null},{"id":"W4245051009","doi":"10.2165/00128413-200514740-00048","title":"Health Canada has approved bortezomib [Velcade; Millennium Pharmaceuticals].","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Healthcare Systems and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bortezomib; Pharmacy; Pharmacology; Family medicine; Oncology; Internal medicine; Multiple myeloma","score_opus":0.22462814122089433,"score_gpt":0.51268809366099,"score_spread":0.28805995244009563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245051009","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04407544,0.011644667,0.00022016863,0.8805992,0.006378014,0.0032001706,0.0003713814,0.00046560308,0.05304535],"genre_scores_gemma":[0.9073851,0.00096752436,0.0007338816,0.07760851,0.0035957075,0.00027500404,0.000048121725,0.00008865047,0.009297472],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99283695,0.0025016477,0.001586074,0.0006188462,0.00073720684,0.0017192968],"domain_scores_gemma":[0.99586207,0.0012976053,0.00075178704,0.0005606549,0.00026111092,0.0012667557],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028696966,0.00038654744,0.0007408319,0.00012355408,0.0018835384,0.000040517552,0.00045024077,0.00027820186,0.0026133591],"category_scores_gemma":[0.00035588362,0.00034904966,0.00009496028,0.00036584778,0.00008067927,0.0003723143,0.000146054,0.0020481627,0.0011110648],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112766545,0.00008256388,0.0035833174,0.0006249676,0.00006373013,0.000022238613,0.0023035433,0.000009665969,0.0002842056,0.0004890336,0.93821245,0.054211516],"study_design_scores_gemma":[0.0016351035,0.000061788385,0.0036913697,0.00015729744,0.000020331247,0.000018274906,0.0020624523,0.00064528757,0.00011396882,0.0000107225505,0.99124056,0.000342856],"about_ca_topic_score_codex":0.6518264,"about_ca_topic_score_gemma":0.71254843,"teacher_disagreement_score":0.8633097,"about_ca_system_score_codex":0.0012831338,"about_ca_system_score_gemma":0.010273721,"threshold_uncertainty_score":0.99989617},"labels":[],"label_agreement":null},{"id":"W4245109221","doi":"10.2165/00128413-200615390-00057","title":"Tequin: labelling updated in Canada","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Horticultural and Viticultural Research","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Labelling; Medicine; Biology; Biochemistry","score_opus":0.023633767765516515,"score_gpt":0.24201085054908436,"score_spread":0.21837708278356785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245109221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99160177,0.00013981771,1.3783533e-7,0.005001363,0.00009401565,0.00014517135,0.000033505537,0.00003684117,0.002947383],"genre_scores_gemma":[0.99757105,0.000019832252,0.000013377669,0.0003250798,0.00024557053,0.000013646832,0.00014661314,7.4852363e-7,0.0016640774],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986314,0.000058040456,0.00025660955,0.0002377117,0.00032786987,0.00048833457],"domain_scores_gemma":[0.9996667,0.00008296937,0.00003805333,0.000031932967,0.00007341643,0.000106938445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011125713,0.00013197401,0.00014863345,0.000008797796,0.000113737035,0.000055284734,0.00023297299,0.000042201864,0.0011840838],"category_scores_gemma":[0.00001645793,0.00004357157,0.000038126607,0.00049820304,0.000024057968,0.00014296568,0.000053734766,0.00018606319,0.00009163731],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027690838,0.00006649234,0.050708514,0.0000055276723,0.0000060379416,0.00013720633,0.000016076672,0.00009474015,0.8881877,0.00013355493,0.03115076,0.029465666],"study_design_scores_gemma":[0.00037498144,0.00007673257,0.7854424,0.000028072165,0.0000063528614,0.000017660937,0.0005390788,0.00063233136,0.054391555,0.00024346654,0.1578225,0.00042483493],"about_ca_topic_score_codex":0.94547683,"about_ca_topic_score_gemma":0.97956055,"teacher_disagreement_score":0.8337962,"about_ca_system_score_codex":0.0002096391,"about_ca_system_score_gemma":0.00006132665,"threshold_uncertainty_score":0.999729},"labels":[],"label_agreement":null},{"id":"W4245182772","doi":"10.2165/00128413-200615530-00070","title":"Product approvals in Canada","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Product (mathematics); Pharmacy; Family medicine; Mathematics","score_opus":0.25689135826693954,"score_gpt":0.3872280217158144,"score_spread":0.13033666344887485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245182772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89781356,0.0031916376,0.00023057777,0.06576224,0.0013249111,0.000862056,0.00025049827,0.000055051336,0.030509457],"genre_scores_gemma":[0.9889086,0.000022591143,0.00067752314,0.0076590492,0.0006095251,0.00011102831,0.000034146375,0.00003054147,0.0019470337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99566746,0.00016237336,0.003053521,0.0005363763,0.00009765833,0.00048260315],"domain_scores_gemma":[0.9982247,0.00028134178,0.00095393334,0.00039986597,0.000034693472,0.000105519364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005789684,0.00016881892,0.00066974293,0.00023382624,0.000075562275,0.00004422807,0.00027813297,0.000047510886,0.0006214075],"category_scores_gemma":[0.0006347407,0.00022859161,0.00005363025,0.0002711494,0.000028267048,0.0003245206,0.00003658746,0.00018045971,0.001241178],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011797816,0.0001160698,0.46539724,0.00024178381,0.000023990291,0.000014023511,0.00025621214,0.0014935608,0.000034042878,0.030424401,0.5015379,0.00044896064],"study_design_scores_gemma":[0.0016003002,0.000023662833,0.4310196,0.000055973313,0.0000041242065,0.000014395726,0.0005219759,0.0048623104,0.0001867856,0.014570908,0.5464289,0.0007110774],"about_ca_topic_score_codex":0.94523555,"about_ca_topic_score_gemma":0.81037414,"teacher_disagreement_score":0.13486142,"about_ca_system_score_codex":0.0017724277,"about_ca_system_score_gemma":0.0009563347,"threshold_uncertainty_score":0.99953645},"labels":[],"label_agreement":null},{"id":"W4245431836","doi":"10.2165/00128413-200715820-00064","title":"Zelnorm withdrawn from the US, Canadian market","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Agricultural safety and regulations","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.010008326148351407,"score_gpt":0.19597577252054346,"score_spread":0.18596744637219206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245431836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414286,0.00022316886,0.0000029397106,0.026422469,0.00026883895,0.00017709323,0.00013727955,0.000057080575,0.031282526],"genre_scores_gemma":[0.9920895,0.000026487778,0.000036988968,0.0024971673,0.0010029894,0.000004235502,0.00013266038,7.118216e-7,0.004209236],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99908286,0.00004023319,0.00016692693,0.00018169345,0.00016899085,0.0003593148],"domain_scores_gemma":[0.99935013,0.0002587172,0.000049677208,0.000052333973,0.000050944735,0.00023818488],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024382542,0.00011825448,0.000087357555,0.0000057536577,0.00064669317,0.00006399211,0.00032489505,0.00008914082,0.0043470566],"category_scores_gemma":[0.000017699394,0.000030139754,0.0000758261,0.0003301725,0.00007959935,0.00011971107,0.000036633308,0.00014846797,0.0001990536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010715767,0.00009442038,0.15889412,0.0000022027452,0.0000969855,0.00006801074,0.0004999822,0.000023670502,0.08305362,0.0009620884,0.4621751,0.29402265],"study_design_scores_gemma":[0.000044135257,0.000012846579,0.58518517,0.0000040120394,0.0000070805577,0.000004991802,0.00017329831,0.000011266394,0.00031704927,0.00014246741,0.4140174,0.000080288555],"about_ca_topic_score_codex":0.21644223,"about_ca_topic_score_gemma":0.6498835,"teacher_disagreement_score":0.4334413,"about_ca_system_score_codex":0.000053079435,"about_ca_system_score_gemma":0.00001652581,"threshold_uncertainty_score":0.9965631},"labels":[],"label_agreement":null},{"id":"W4246402844","doi":"10.2165/00128413-200012350-00055","title":"Canadian market news","year":2000,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Advertising; Family medicine; Business","score_opus":0.014479951548192791,"score_gpt":0.2920210984169048,"score_spread":0.277541146868712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246402844","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047151603,0.00018297776,9.68133e-7,0.040916078,0.00029786094,0.00011197861,0.000017333685,0.00004789923,0.9112733],"genre_scores_gemma":[0.8074815,0.00025638688,0.0000537222,0.0016291452,0.00057975075,0.000007906069,0.0000023120047,0.0000061600995,0.18998308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99926955,0.00006676718,0.000086597705,0.00010981508,0.00015178452,0.00031551108],"domain_scores_gemma":[0.9995759,0.00002741015,0.000012247506,0.00008505748,0.000033793716,0.0002655889],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015307922,0.000056197765,0.00006566279,0.000041611493,0.0008883583,0.000057402038,0.00011798985,0.00004329592,0.035541292],"category_scores_gemma":[0.000019042383,0.000051943334,0.000044905613,0.00022167532,0.000105473795,0.00012288785,0.000007136068,0.00006837475,0.00064216845],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006038151,0.000012384501,0.0024555991,0.0000016063177,0.000016018284,0.000032336367,0.004619231,0.000008922425,0.0000051356265,0.0029849391,0.90379286,0.08606493],"study_design_scores_gemma":[0.00009906079,0.000005494374,0.0062321867,0.0000025798684,0.000006630705,0.0000011902166,0.0010506582,0.00002026639,0.0000022472564,0.00027485556,0.9922266,0.0000782279],"about_ca_topic_score_codex":0.7191387,"about_ca_topic_score_gemma":0.83409667,"teacher_disagreement_score":0.7603299,"about_ca_system_score_codex":0.00015382594,"about_ca_system_score_gemma":0.00032123426,"threshold_uncertainty_score":0.9653404},"labels":[],"label_agreement":null},{"id":"W4246404833","doi":"10.2165/00128413-200113070-00051","title":"Canadian market news","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Legal case studies and regulations","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Family medicine","score_opus":0.022353605644887777,"score_gpt":0.30974312144010446,"score_spread":0.2873895157952167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246404833","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035926256,0.00022046642,0.000009543679,0.063224085,0.00062662346,0.00012266652,0.000009994393,0.00005294546,0.8998074],"genre_scores_gemma":[0.908626,0.00031704202,0.000058177873,0.0015617765,0.00073611556,0.000008241729,0.0000021103735,0.0000064422916,0.088684075],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992443,0.000062916944,0.00008734468,0.00010933204,0.00015943646,0.0003367058],"domain_scores_gemma":[0.9995231,0.000033568485,0.000019951282,0.00008577111,0.000056364286,0.00028124367],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001821228,0.00005687701,0.00006681867,0.0000619321,0.00089069887,0.000058235637,0.00012030452,0.000044115037,0.0050061303],"category_scores_gemma":[0.000047453144,0.000052514963,0.00004454954,0.00029058653,0.00009916184,0.00012869124,0.000016126643,0.000069618545,0.0002374407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000065401778,0.000015341353,0.021148097,0.0000016256698,0.00001987323,0.000099789395,0.0042653675,0.000004818529,0.0000132992,0.00789336,0.94677347,0.019758416],"study_design_scores_gemma":[0.000103957515,0.000005591364,0.010776674,0.0000025474646,0.000006810139,0.0000030986496,0.0023189462,0.000020300724,0.0000017644303,0.00035909493,0.9863224,0.00007883619],"about_ca_topic_score_codex":0.7221024,"about_ca_topic_score_gemma":0.90812033,"teacher_disagreement_score":0.87269974,"about_ca_system_score_codex":0.00019236613,"about_ca_system_score_gemma":0.00033669223,"threshold_uncertainty_score":0.99590343},"labels":[],"label_agreement":null},{"id":"W4246656322","doi":"10.2165/00128413-200816340-00067","title":"Tacrolimus ER launched in Canada for renal transplant.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Organ Donation and Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Launched; Tacrolimus; Renal transplant; Pharmacy; Family medicine; Internal medicine; Transplantation; Engineering","score_opus":0.023990365395594605,"score_gpt":0.2569539376459265,"score_spread":0.2329635722503319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246656322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942723,0.000077783916,0.00043386378,0.0030861725,0.00018016374,0.0003455384,0.00010788327,0.000029994037,0.0014663069],"genre_scores_gemma":[0.9968216,0.0000940997,0.00027146217,0.001819531,0.0001039952,0.0000121325675,0.00015300617,0.000016116666,0.0007080553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992583,0.000015408388,0.00020534337,0.00014267297,0.00019193262,0.00018637176],"domain_scores_gemma":[0.99969655,0.0000592466,0.000028931943,0.000074101394,0.00004745575,0.00009370509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006176487,0.000091189664,0.00015499644,0.00007872265,0.00004366562,0.0000029568512,0.000044630095,0.000036822294,0.00030116626],"category_scores_gemma":[0.000009629901,0.00008634646,0.00003762664,0.00012835424,0.000018017317,0.000056914007,0.0000016349246,0.00011097474,0.000014695977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076190424,0.00087632943,0.62866086,0.0010019612,0.0004226368,0.008260872,0.01217405,0.00042454945,0.22572058,0.000653996,0.0971027,0.017082438],"study_design_scores_gemma":[0.01669268,0.00016160638,0.86492044,0.00012074581,0.0001260345,0.0011104487,0.00016039814,0.0016643768,0.07259636,0.000047517206,0.042067803,0.00033158562],"about_ca_topic_score_codex":0.11508224,"about_ca_topic_score_gemma":0.31323066,"teacher_disagreement_score":0.23625961,"about_ca_system_score_codex":0.00015054658,"about_ca_system_score_gemma":0.000741438,"threshold_uncertainty_score":0.8908105},"labels":[],"label_agreement":null},{"id":"W4246947765","doi":"10.2165/00128413-200816260-00082","title":"Extended-release bupropion approved for SAD in Canada.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Poisoning and overdose treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bupropion; Medicine; Pharmacology; Psychiatry; Smoking cessation","score_opus":0.026465223979017967,"score_gpt":0.27019203197768576,"score_spread":0.2437268079986678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246947765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605185,0.0003563309,0.00007757192,0.0012572741,0.00023841338,0.00051541306,0.000030446854,0.00004488012,0.0014278177],"genre_scores_gemma":[0.99472785,0.000061678955,0.0005335134,0.0010907208,0.00011618666,0.000087740926,0.000046413665,0.000023831013,0.0033120913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990449,0.000018077231,0.00020595844,0.00022718101,0.0001927369,0.00031116517],"domain_scores_gemma":[0.99950665,0.000052822637,0.000047146696,0.00017841038,0.000046717912,0.00016823823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049695664,0.0001390629,0.00023785842,0.00006678846,0.000065837645,0.0000035669677,0.00006167116,0.00004159908,0.00004567058],"category_scores_gemma":[0.00007667344,0.00011884892,0.000053441523,0.00012684973,0.000023646093,0.000052979794,0.000014622175,0.000121073484,0.000021690252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061808634,0.0024223828,0.48750976,0.0005506398,0.00045577198,0.005524388,0.0015724251,0.00009947646,0.02939955,0.00015728359,0.30250794,0.16361953],"study_design_scores_gemma":[0.018499741,0.00051875896,0.8866219,0.00021113886,0.00013646935,0.00042522937,0.00028036954,0.0042653913,0.024811024,0.000068257796,0.06372982,0.0004318831],"about_ca_topic_score_codex":0.43458006,"about_ca_topic_score_gemma":0.13148968,"teacher_disagreement_score":0.39911216,"about_ca_system_score_codex":0.00053346105,"about_ca_system_score_gemma":0.0011762074,"threshold_uncertainty_score":0.8843584},"labels":[],"label_agreement":null},{"id":"W4247561095","doi":"10.2165/00128413-200313820-00041","title":"A new 20mg formulation of doxycycline hyclate ['Periostat'; CollaGenex Pharmaceuticals] has been approved in Canada","year":2003,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Doxycycline; Pharmacy; Pharmacology; Family medicine; Antibiotics; Microbiology","score_opus":0.05076536241035398,"score_gpt":0.3241503845011009,"score_spread":0.2733850220907469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247561095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795439,0.0006779185,0.001382735,0.007363692,0.00014057054,0.000969506,0.00006420157,0.00004630704,0.009811171],"genre_scores_gemma":[0.99531406,0.000086721775,0.0021191922,0.0010222311,0.00010927027,0.000045806763,0.000048664282,0.000029748819,0.0012243052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982063,0.000050454713,0.00065839675,0.00033149403,0.00034692208,0.00040642355],"domain_scores_gemma":[0.9988526,0.00014093555,0.00013634178,0.00029017517,0.00009485336,0.00048509354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020574388,0.00022035411,0.00041593311,0.000070485,0.00006434487,0.000015352,0.00013456513,0.0000884987,0.00095904095],"category_scores_gemma":[0.00013386486,0.00021789064,0.00008238019,0.0005650547,0.00005592712,0.000094711686,0.000024233808,0.00032003594,0.000017003284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005343879,0.00033212508,0.019998495,0.00029504954,0.00012293756,0.00009421369,0.00016598443,0.00042326373,0.95151746,0.0005493198,0.016637458,0.0093293125],"study_design_scores_gemma":[0.0065323208,0.000053017637,0.009428086,0.00006805579,0.00017719214,0.0000796494,0.00014603382,0.006747858,0.7340543,0.00020252106,0.24220619,0.00030474094],"about_ca_topic_score_codex":0.04703852,"about_ca_topic_score_gemma":0.015721815,"teacher_disagreement_score":0.22556873,"about_ca_system_score_codex":0.00037706344,"about_ca_system_score_gemma":0.0021608772,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W4247698475","doi":"10.2165/00128413-200615670-00056","title":"Health Canada updates information about Tamiflu","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Health information; Medical emergency; Environmental health; Family medicine; Health care; Economic growth","score_opus":0.12867541220596318,"score_gpt":0.37661253920261634,"score_spread":0.24793712699665316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247698475","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3740215,0.008739797,0.007734822,0.54029006,0.0049082492,0.002113841,0.0035590846,0.00036879466,0.058263883],"genre_scores_gemma":[0.92286056,0.000104294966,0.0011431362,0.073441654,0.0006499029,0.00008338465,0.0004889356,0.000029225663,0.0011988994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99502105,0.00014953857,0.0038694113,0.00029380067,0.0001339875,0.0005322273],"domain_scores_gemma":[0.99704635,0.00024611485,0.0020675454,0.00036431503,0.00007326351,0.00020241778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00517687,0.00019162857,0.00069659424,0.0002391353,0.00026713504,0.00012759138,0.00027574215,0.00007816273,0.0006327571],"category_scores_gemma":[0.0004242832,0.00025547136,0.00006835386,0.00021417416,0.00003650789,0.0011654774,0.000039872633,0.0001739646,0.0026701833],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000051727006,0.000029513472,0.023757122,0.00019135012,0.000019413756,7.432982e-7,0.0002879238,0.0004320676,9.93472e-7,0.045327257,0.929329,0.0006194494],"study_design_scores_gemma":[0.00065355765,0.00002493537,0.08392541,0.00003068949,0.0000018719509,0.0000061314563,0.00026317936,0.0026654291,0.000012168835,0.0033110813,0.9088257,0.00027985196],"about_ca_topic_score_codex":0.77851844,"about_ca_topic_score_gemma":0.28752944,"teacher_disagreement_score":0.5488391,"about_ca_system_score_codex":0.0013450644,"about_ca_system_score_gemma":0.00096741266,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W4247747570","doi":"10.2165/00128413-200514910-00054","title":"Omalizumab [Xolair; Novartis] has been launched in Canada for the treatment of moderate-to-severe, persistent asthma","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Omalizumab; Medicine; Asthma; Mepolizumab; Launched; Pharmacy; Family medicine; Internal medicine; Immunology; Immunoglobulin E","score_opus":0.03356341046701216,"score_gpt":0.27641877988716185,"score_spread":0.24285536942014968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247747570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98768127,0.0021474084,0.000087099936,0.008250366,0.0001388564,0.0011702004,0.0001465394,0.000018729812,0.00035950253],"genre_scores_gemma":[0.9967626,0.00004149608,0.00023894751,0.0016536489,0.00025310257,0.000096302465,0.000020219304,0.0000271291,0.00090657885],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872994,0.000034010653,0.00035830965,0.000254582,0.0002872844,0.0003358857],"domain_scores_gemma":[0.99918514,0.00011194997,0.00007501114,0.00028294817,0.00011171976,0.00023324303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007006494,0.00019724393,0.00035455028,0.0000802984,0.00010365137,0.0000144497235,0.00011770443,0.000042231164,0.00023229305],"category_scores_gemma":[0.000025890411,0.0001291986,0.00019330224,0.00016550659,0.000051904513,0.000051064468,0.000018360546,0.00006349709,0.000017550348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016620906,0.005929368,0.058909297,0.00050422904,0.0015909383,0.0005954867,0.009157894,0.049407907,0.010905352,0.00012299525,0.08793386,0.75832176],"study_design_scores_gemma":[0.018599907,0.003291761,0.12831719,0.00015777854,0.00045709714,0.000085842876,0.0038496389,0.028762048,0.019038688,0.000009341111,0.7969009,0.00052979036],"about_ca_topic_score_codex":0.13052826,"about_ca_topic_score_gemma":0.3123615,"teacher_disagreement_score":0.757792,"about_ca_system_score_codex":0.0007910185,"about_ca_system_score_gemma":0.0014786661,"threshold_uncertainty_score":0.8752616},"labels":[],"label_agreement":null},{"id":"W4247784427","doi":"10.2165/00128413-200414660-00007","title":"Additional pertussis booster warranted among Canadian teens","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Booster (rocketry); Family medicine; Pediatrics","score_opus":0.01120816360198514,"score_gpt":0.22021411404630223,"score_spread":0.20900595044431708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247784427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97526914,0.00016234198,0.000018876546,0.0034021304,0.0021870893,0.00020611196,0.008944799,0.00015346947,0.009656066],"genre_scores_gemma":[0.99151987,0.000009722627,0.000030938216,0.0006593492,0.00017588594,0.000058983154,0.0031094612,0.000017338709,0.004418433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992233,0.00004192858,0.00017601252,0.00019773138,0.000012342477,0.0003486659],"domain_scores_gemma":[0.99962485,0.000048588503,0.00004323091,0.00014182887,0.00007250118,0.00006901574],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00004485513,0.00014058361,0.0001434975,0.00016506405,0.0003060136,0.000026420103,0.00011151248,0.00017664804,0.17064457],"category_scores_gemma":[0.000039783976,0.00012447232,0.00008426262,0.00012764586,0.00009318682,0.00015690694,0.000022682683,0.00020884251,0.0033981295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052603285,0.00011995094,0.0028929089,0.000007542173,0.00021381382,0.000017724751,0.00024663672,0.000008289816,0.15827397,0.00028002716,0.8349558,0.0029307117],"study_design_scores_gemma":[0.0012437205,0.00006463623,0.08195864,0.00003322938,0.000024745712,0.00015554696,0.00006858812,0.0000010521103,0.010129488,0.000097222786,0.90601104,0.0002120788],"about_ca_topic_score_codex":0.047355864,"about_ca_topic_score_gemma":0.056076437,"teacher_disagreement_score":0.16724643,"about_ca_system_score_codex":0.000098566336,"about_ca_system_score_gemma":0.0001637473,"threshold_uncertainty_score":0.9973778},"labels":[],"label_agreement":null},{"id":"W4248294968","doi":"10.2165/00128413-200816330-00064","title":"Zotarolimus-eluting stent approved for CAD in Canada.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Zotarolimus; CAD; Pharmacy; Medical physics; Stent; Internal medicine; Drug-eluting stent; Family medicine; Engineering; Engineering drawing","score_opus":0.04155910093374337,"score_gpt":0.2865467605291062,"score_spread":0.24498765959536284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248294968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382955,0.00051458844,0.000244285,0.002882996,0.00036924356,0.00051222247,0.000056983994,0.000025488338,0.0015646522],"genre_scores_gemma":[0.9965899,0.00006691259,0.00049102,0.0011102697,0.000158902,0.000078456214,0.00003560568,0.00001807444,0.001450868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999065,0.000014881794,0.00030853463,0.0001740386,0.00015875009,0.00027883745],"domain_scores_gemma":[0.9994335,0.00015342858,0.000054657972,0.00015306236,0.000082584374,0.0001227385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008353681,0.00010702444,0.00020497576,0.0000718506,0.00006621896,0.0000040454224,0.00007008881,0.00003200186,0.00013425463],"category_scores_gemma":[0.00015533656,0.0001029014,0.000086594,0.00011635709,0.00002130327,0.000039370938,0.000029577925,0.00013602918,0.0000105886365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010778921,0.001374789,0.66537464,0.00059275323,0.00020718251,0.0026131715,0.0011135497,0.0005272145,0.0052906154,0.0003007488,0.25551948,0.066007994],"study_design_scores_gemma":[0.012742278,0.00075248483,0.7046304,0.00046335917,0.00017044035,0.00083672034,0.0014920734,0.019817619,0.004235689,0.00008765403,0.25422445,0.0005468412],"about_ca_topic_score_codex":0.37430355,"about_ca_topic_score_gemma":0.4260026,"teacher_disagreement_score":0.06546115,"about_ca_system_score_codex":0.00032334775,"about_ca_system_score_gemma":0.0008150073,"threshold_uncertainty_score":0.629863},"labels":[],"label_agreement":null},{"id":"W4248304185","doi":"10.2165/00128413-200615450-00013","title":"Immunising healthy infants against influenza not worth it in Canada?","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Environmental health; Family medicine","score_opus":0.0779504830436148,"score_gpt":0.3805162292940481,"score_spread":0.3025657462504333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248304185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723257,0.0017696479,0.0000030415617,0.0056778397,0.00020961047,0.0005789433,0.000043993066,0.000059721267,0.019331494],"genre_scores_gemma":[0.96674746,0.0002469142,0.00018705789,0.032049183,0.00025021433,0.000051805455,0.000020031115,0.00004375458,0.0004035568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691415,0.00011609324,0.00076085445,0.00036033313,0.000862532,0.0009860613],"domain_scores_gemma":[0.99880224,0.0001949386,0.0001307619,0.00043833186,0.00020404944,0.00022966054],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047118837,0.00027973164,0.0005257532,0.00034047884,0.00019544025,0.000033790857,0.00022567667,0.0000752652,0.000117200725],"category_scores_gemma":[0.00020795729,0.00026561713,0.00007102122,0.0006210268,0.00011308523,0.00018616772,0.00018363343,0.0007434904,0.00009728933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003149859,0.00037866412,0.85107493,0.000474893,0.00018664016,0.002082846,0.0007771574,0.0010186302,0.023522498,0.00011269799,0.08836173,0.02885945],"study_design_scores_gemma":[0.005681703,0.00012073451,0.7253316,0.0003129629,0.00002312659,0.000023228358,0.00061768555,0.00053698814,0.004157574,0.000015994226,0.26280537,0.0003730356],"about_ca_topic_score_codex":0.84303683,"about_ca_topic_score_gemma":0.76214063,"teacher_disagreement_score":0.17444363,"about_ca_system_score_codex":0.0016022063,"about_ca_system_score_gemma":0.0030345875,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W4248712378","doi":"10.2165/00128413-200515060-00051","title":"Safety updates to Canadian labelling for Duragesic","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Labelling; Medicine; Pharmacy; Medical emergency; Family medicine; Criminology; Psychology","score_opus":0.02394607577086246,"score_gpt":0.3393357333737358,"score_spread":0.31538965760287335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248712378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7354955,0.0015931283,0.00033315184,0.23802285,0.0011204424,0.002267177,0.0003426998,0.00018507574,0.020639988],"genre_scores_gemma":[0.961655,0.000086361215,0.0023624017,0.02247661,0.001315806,0.00012398743,0.00011535383,0.00003250989,0.011831963],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99911976,0.000012706321,0.00018047138,0.0002117146,0.00007995604,0.0003954086],"domain_scores_gemma":[0.9992224,0.0000625953,0.000025613055,0.00012328694,0.00008066996,0.00048545783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000107718326,0.00013042781,0.00019846663,0.00015341995,0.00011750203,0.000012764475,0.00007587857,0.000053576397,0.0018451003],"category_scores_gemma":[0.000017719549,0.00012277786,0.00007110157,0.00014976675,0.000017358947,0.000060563965,0.000011997696,0.00009599852,0.00051055715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013749792,0.00025820584,0.0046583093,0.000076357406,0.00032370092,0.00010422281,0.0008582624,0.00027999142,0.04311016,0.0003369931,0.84337586,0.10524296],"study_design_scores_gemma":[0.0029060624,0.00024207338,0.0022792532,0.000018762734,0.00015836893,0.00002943339,0.000025638212,0.00034154806,0.02560659,0.000023696322,0.96823645,0.0001321076],"about_ca_topic_score_codex":0.0068078693,"about_ca_topic_score_gemma":0.025523786,"teacher_disagreement_score":0.22615953,"about_ca_system_score_codex":0.00040171377,"about_ca_system_score_gemma":0.00028671572,"threshold_uncertainty_score":0.99980587},"labels":[],"label_agreement":null},{"id":"W4248803141","doi":"10.2165/00128413-200213480-00012","title":"Amiodarone lowers costs for atrial fibrillation in Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Amiodarone; Atrial fibrillation; Cardiology; Internal medicine; Dronedarone; Pharmacy; Family medicine","score_opus":0.06332727414332998,"score_gpt":0.3143081856551948,"score_spread":0.25098091151186486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248803141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733213,0.00054245046,0.00020083605,0.019238241,0.0012405758,0.0013726988,0.00002465281,0.000060444487,0.003998758],"genre_scores_gemma":[0.99329907,0.00009485389,0.000307959,0.0004323546,0.0016446728,0.000001930847,0.000040701074,0.000018215582,0.00416025],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901813,0.000023306115,0.00031072617,0.00017996728,0.00023726773,0.00023058562],"domain_scores_gemma":[0.99949914,0.00015948564,0.00008050534,0.00012636396,0.00004612851,0.00008839774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012669194,0.00011402138,0.00024172182,0.00011151454,0.00004306434,0.000013886721,0.00004614507,0.000039219438,0.00057315396],"category_scores_gemma":[0.00013282725,0.00011122185,0.00012044503,0.00020844654,0.000013148868,0.00011246975,0.00001834454,0.0000618719,0.000046468103],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008028054,0.000003891433,0.817778,0.00008953665,0.0001130321,0.000041397812,0.00012532117,0.0018999623,0.00074077945,0.00021096015,0.088023,0.09017133],"study_design_scores_gemma":[0.013903893,0.00019583982,0.28919896,0.00006969515,0.00018457691,0.000010966081,0.00019890674,0.045792084,0.0005937487,0.000063804284,0.64940387,0.0003836426],"about_ca_topic_score_codex":0.13059743,"about_ca_topic_score_gemma":0.13160866,"teacher_disagreement_score":0.56138086,"about_ca_system_score_codex":0.00059329043,"about_ca_system_score_gemma":0.00012656153,"threshold_uncertainty_score":0.88423723},"labels":[],"label_agreement":null},{"id":"W4248864116","doi":"10.2165/00128413-200816340-00055","title":"Health Canada issues foreign product alert","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Product (mathematics); Medical emergency; Family medicine","score_opus":0.051277173733828965,"score_gpt":0.3116325408963768,"score_spread":0.26035536716254787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248864116","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17567208,0.0018402443,0.00003902815,0.7337944,0.0019181208,0.0006011946,0.000017653723,0.0002843577,0.08583295],"genre_scores_gemma":[0.74507403,0.0002100798,0.00010477329,0.2494506,0.003740911,0.000023874089,0.00004523733,0.000025261214,0.0013252475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804145,0.00003410524,0.00048111644,0.00032246302,0.0002564769,0.0008643945],"domain_scores_gemma":[0.999227,0.0000386478,0.00024140348,0.00027529435,0.00014614043,0.0000715499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005300528,0.00019432555,0.00039202292,0.00010155952,0.00044569172,0.00003637971,0.00030651595,0.000039271792,0.000284667],"category_scores_gemma":[0.00025996057,0.00017233372,0.000051077983,0.00037726836,0.000072286064,0.00047248232,0.00012785364,0.0001817192,0.00027535053],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008779272,0.000023855471,0.009809329,0.00011585686,0.000010897,0.000021341926,0.000015905913,0.00010759464,0.0000050469184,0.0060336753,0.9820427,0.0018050552],"study_design_scores_gemma":[0.00025984718,0.00000985326,0.021236539,0.000012157257,0.0000037569273,0.000028265056,0.000085946056,0.0009497339,0.000004508994,0.00039803894,0.97684276,0.00016859958],"about_ca_topic_score_codex":0.962603,"about_ca_topic_score_gemma":0.24664837,"teacher_disagreement_score":0.7159546,"about_ca_system_score_codex":0.00014505131,"about_ca_system_score_gemma":0.0005768234,"threshold_uncertainty_score":0.7670983},"labels":[],"label_agreement":null},{"id":"W4249028562","doi":"10.2165/00128413-200615330-00059","title":"Health Canada has received 29 domestic reports of suspected isotretinoin [Accutane]-associated vascular disorders","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Acne and Rosacea Treatments and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Isotretinoin; Dermatology; Acne","score_opus":0.007453704686786261,"score_gpt":0.24865689757772944,"score_spread":0.24120319289094316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249028562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98684007,0.0017593303,0.000019488556,0.0077356296,0.0003963755,0.0006876045,0.000036224654,0.00009663015,0.0024286662],"genre_scores_gemma":[0.9973923,0.00019521691,0.000092349896,0.0005615777,0.00010093187,0.000017561342,0.00036269487,0.00003763498,0.0012397156],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9980134,0.000110243665,0.0006018954,0.00034531907,0.00045584273,0.00047329467],"domain_scores_gemma":[0.9988653,0.00009431474,0.00038334745,0.00032744213,0.000121552366,0.0002080556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021539326,0.00025078832,0.00065030146,0.000094298375,0.0001845288,0.000015184342,0.00006230583,0.0000905666,0.00015396306],"category_scores_gemma":[0.00012033695,0.00020166422,0.00015236594,0.00038638318,0.00008057754,0.00005092965,0.000025310146,0.00019231925,0.0000051594334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041266394,0.002470402,0.40436321,0.0005453235,0.0012931792,0.004430368,0.0004889637,0.00041528346,0.0065989853,0.000031809657,0.57272834,0.006221473],"study_design_scores_gemma":[0.008098308,0.0011860187,0.93552196,0.00049612013,0.00061361626,0.0004592521,0.0002150551,0.00035720886,0.002200889,0.0003467479,0.04994825,0.00055655604],"about_ca_topic_score_codex":0.636601,"about_ca_topic_score_gemma":0.3206251,"teacher_disagreement_score":0.53115875,"about_ca_system_score_codex":0.0004086687,"about_ca_system_score_gemma":0.0013038268,"threshold_uncertainty_score":0.82236284},"labels":[],"label_agreement":null},{"id":"W4249598482","doi":"10.1007/bf03272663","title":"Atorvastatin calcium approved in Canada for MI prevention","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Atorvastatin; Pharmacy; Pharmacology; Internal medicine; Family medicine","score_opus":0.01454379219708397,"score_gpt":0.2792005168786046,"score_spread":0.2646567246815206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249598482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323285,0.00007037674,0.0054037445,0.00008640095,0.00024155379,0.00036343132,0.000043515138,0.000006684426,0.0005514221],"genre_scores_gemma":[0.99808186,0.0000025574777,0.0005860837,0.0004180274,0.00017581678,0.000024534762,0.00012605757,0.000020277257,0.0005647999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915767,0.000029000685,0.00022208232,0.00021091691,0.000098710254,0.0002816392],"domain_scores_gemma":[0.99961156,0.000013551661,0.000062877385,0.00015528144,0.000055544213,0.00010121686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025794603,0.00010214885,0.00007413496,0.000030001638,0.00003099736,0.0000075398234,0.000112819784,0.000052562078,0.000024855955],"category_scores_gemma":[0.00005659463,0.000115880386,0.00005079395,0.000046229365,0.000016236474,0.0000035608625,0.00003176654,0.000050740953,0.0000040005752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017070762,0.00016410617,0.057470486,0.00018200246,0.000076527096,0.00023834386,0.00011930131,0.00017881932,0.867383,0.00011660544,0.058324456,0.014039271],"study_design_scores_gemma":[0.00469394,0.00014104998,0.40365964,0.000030465975,0.00003564137,0.00001085321,0.00064744195,0.0005760939,0.48940876,0.00018479621,0.099999346,0.000611952],"about_ca_topic_score_codex":0.035756644,"about_ca_topic_score_gemma":0.5832056,"teacher_disagreement_score":0.54744893,"about_ca_system_score_codex":0.00010042181,"about_ca_system_score_gemma":0.0007239748,"threshold_uncertainty_score":0.9706643},"labels":[],"label_agreement":null},{"id":"W4249991781","doi":"10.2165/00128413-200414460-00045","title":"Product approvals in Canada","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Product (mathematics); Pharmacy; Family medicine","score_opus":0.3188622538745315,"score_gpt":0.4054423090858969,"score_spread":0.08658005521136541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249991781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8740571,0.002341437,0.0003821845,0.11037504,0.0013697858,0.00086479576,0.0001801715,0.00004993927,0.010379537],"genre_scores_gemma":[0.98303187,0.000052325995,0.001114431,0.014817183,0.0003565233,0.00011081601,0.000017151933,0.000030400022,0.00046929147],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959922,0.00011324748,0.0027632227,0.00054860173,0.000099044024,0.00048370057],"domain_scores_gemma":[0.99832445,0.00018426792,0.0008581484,0.00042744243,0.000033884608,0.00017179408],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057095936,0.00017056087,0.000675331,0.00023100952,0.00007795889,0.000039522183,0.0003112291,0.000048613256,0.000434491],"category_scores_gemma":[0.0011691457,0.00023000746,0.00005443855,0.0002841303,0.000030402123,0.00037491345,0.00004168367,0.00021227283,0.0016534709],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006503259,0.0005640724,0.5336049,0.0012122666,0.00018746269,0.00008916001,0.005511946,0.019114895,0.0001294752,0.16588263,0.27113217,0.0025059485],"study_design_scores_gemma":[0.007382239,0.000105385036,0.377869,0.0002651319,0.000010932151,0.000057158668,0.0030395952,0.0022913897,0.00073312316,0.061529156,0.5448451,0.0018717964],"about_ca_topic_score_codex":0.8873326,"about_ca_topic_score_gemma":0.7097646,"teacher_disagreement_score":0.27371293,"about_ca_system_score_codex":0.0030031113,"about_ca_system_score_gemma":0.001830376,"threshold_uncertainty_score":0.9991239},"labels":[],"label_agreement":null},{"id":"W4250118342","doi":"10.2165/00128413-200615470-00054","title":"Safety information on gadodiamide issued in Canada","year":2006,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gadodiamide; Pharmacy; Physical therapy; Family medicine; Radiology; Magnetic resonance imaging","score_opus":0.015536238022708234,"score_gpt":0.3189604577555457,"score_spread":0.30342421973283745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250118342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89429116,0.000024539528,0.00015443563,0.004975029,0.002067571,0.00052497484,0.00007252054,0.00009239379,0.097797394],"genre_scores_gemma":[0.9937664,0.000010239947,0.00013350569,0.004154875,0.00031669153,0.000035943543,0.00009127764,0.000015744376,0.0014753074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9980922,0.00015552425,0.0007422235,0.00014325486,0.0003512029,0.000515599],"domain_scores_gemma":[0.99872136,0.0006989973,0.00020261561,0.00019826263,0.00009477217,0.00008397468],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037551794,0.00015300325,0.00021641489,0.00016195298,0.00023109182,0.000008079016,0.00016396817,0.000082246355,0.00068956835],"category_scores_gemma":[0.00020792184,0.00014609621,0.000025106001,0.00026301912,0.000017028622,0.0002423921,0.000047110854,0.0005288479,0.0013745589],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000729446,0.000102088256,0.44862953,0.0002832099,0.00002026282,0.00010821818,0.0015909986,0.0047006086,0.00033476218,0.0031578946,0.5302992,0.010043797],"study_design_scores_gemma":[0.0030040662,0.000026228217,0.632364,0.00026976343,0.000008937904,0.0000025236866,0.0012677092,0.0018456801,0.00033257226,0.0001803925,0.36044484,0.00025333572],"about_ca_topic_score_codex":0.91750365,"about_ca_topic_score_gemma":0.86099684,"teacher_disagreement_score":0.18373442,"about_ca_system_score_codex":0.0008507868,"about_ca_system_score_gemma":0.0030079987,"threshold_uncertainty_score":0.999403},"labels":[],"label_agreement":null},{"id":"W4250267269","doi":"10.2165/00128413-200112860-00058","title":"Recent approvals in the Canadian market","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine","score_opus":0.02371898196635164,"score_gpt":0.279133966060813,"score_spread":0.25541498409446134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250267269","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14211012,0.001659076,0.0000057420425,0.4899582,0.00029091793,0.00037950493,0.000002300612,0.000057614776,0.3655365],"genre_scores_gemma":[0.9721356,0.0041563795,0.00006398586,0.018293386,0.00009438754,0.000018942143,0.0000067499745,0.000008675255,0.0052219103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933016,0.0000487884,0.00013113664,0.00012916465,0.00010226663,0.00025847688],"domain_scores_gemma":[0.99962515,0.000028790484,0.000020185287,0.00021495455,0.000024924084,0.00008600237],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003713328,0.00007605385,0.00010772893,0.00015010862,0.000083576815,0.000009102864,0.000138938,0.0009780078,0.0015774696],"category_scores_gemma":[0.000053341668,0.00004882873,0.000030399495,0.00038556373,0.00007636039,0.000024105722,0.00001134131,0.0017274374,0.0001500556],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032504406,0.00029811374,0.033236966,0.000029673165,0.000121349476,0.004003272,0.0009980198,0.0000031670327,0.0010317529,0.0022956177,0.6615985,0.2960585],"study_design_scores_gemma":[0.0006891439,0.000049422284,0.035362843,0.000022850429,0.000023783674,0.0006003084,0.00018251906,0.00009334672,0.00030897875,0.00014152877,0.9624616,0.00006366045],"about_ca_topic_score_codex":0.008265064,"about_ca_topic_score_gemma":0.03454945,"teacher_disagreement_score":0.8300255,"about_ca_system_score_codex":0.00006648704,"about_ca_system_score_gemma":0.00015351386,"threshold_uncertainty_score":0.9993352},"labels":[],"label_agreement":null},{"id":"W4250351784","doi":"10.2165/00128413-200414390-00057","title":"A blueprint for the Canadian Medication Incident Reporting and Prevention System (CMIRPS) has been developed","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blueprint; Medicine; Pharmacy; Family medicine; Medical emergency; Engineering","score_opus":0.2836038758750553,"score_gpt":0.44070278801471624,"score_spread":0.15709891213966093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250351784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.911052,0.0006328434,0.01492694,0.06792134,0.0006327088,0.0029397286,0.00001055467,0.00011039925,0.0017734753],"genre_scores_gemma":[0.9955401,0.000038980856,0.0027545,0.0011592045,0.00017021198,0.00014460362,0.000022373026,0.000015865442,0.00015415074],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99864215,0.000038405808,0.00061145634,0.0002106648,0.00025962217,0.00023771705],"domain_scores_gemma":[0.9986882,0.00017857164,0.00054524915,0.00017432547,0.0001234189,0.00029023836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012781643,0.000108634114,0.00018504573,0.00007317355,0.00039956963,0.000067383,0.000080299564,0.00006518559,0.00002518565],"category_scores_gemma":[0.00093726575,0.00007634538,0.000063120264,0.00010221364,0.000061707826,0.00013421064,0.00003566044,0.00020263463,0.000019906725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026770025,0.00077882677,0.39616653,0.0057882797,0.0027962904,0.0008940358,0.015457379,0.00047523237,0.02162268,0.03770739,0.0054908623,0.5101455],"study_design_scores_gemma":[0.013959076,0.00059070246,0.68227583,0.0011922298,0.0018770257,0.001452381,0.0030429517,0.01082951,0.01455379,0.002698742,0.26687542,0.0006523604],"about_ca_topic_score_codex":0.018231586,"about_ca_topic_score_gemma":0.015581201,"teacher_disagreement_score":0.5094931,"about_ca_system_score_codex":0.0003948837,"about_ca_system_score_gemma":0.0007402066,"threshold_uncertainty_score":0.9883061},"labels":[],"label_agreement":null},{"id":"W4252046852","doi":"10.2165/00128413-200715940-00063","title":"Health Canada has issued a Qualifying Notice for the approval of dronabinol/cannabidiol","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cannabidiol; Dronabinol; Medicine; Notice; Pharmacy; Cannabis; Family medicine; Psychiatry; Law; Internal medicine; Cannabinoid; Political science","score_opus":0.05891339858623662,"score_gpt":0.37029963544527245,"score_spread":0.3113862368590358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252046852","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39690104,0.008242351,0.007753097,0.5779463,0.001534554,0.005245136,0.00022862764,0.000107529726,0.0020413727],"genre_scores_gemma":[0.9800156,0.00004899017,0.00048710898,0.0054997783,0.00068255106,0.00012040194,0.000027434502,0.000054777007,0.013063404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973972,0.00006363932,0.00061407796,0.00031518683,0.00081865815,0.00079123443],"domain_scores_gemma":[0.9984117,0.00014234504,0.00020277618,0.00044241452,0.00042170985,0.00037903507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019482595,0.00019590459,0.0004659859,0.000117955904,0.0003099798,0.00003054657,0.00028307532,0.000073316914,0.00010702595],"category_scores_gemma":[0.0003344026,0.00014097687,0.00016543397,0.0003951461,0.00020428361,0.000052810505,0.00007046924,0.00037342857,0.000004221354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011792858,0.00018594899,0.0013937133,0.0009469082,0.00016849142,0.00004303486,0.0012021136,0.00003221281,0.005834623,0.00032659012,0.8994068,0.08928028],"study_design_scores_gemma":[0.0029546074,0.000517859,0.025272923,0.00008442398,0.000076212855,0.000086871834,0.0022107537,0.00087757764,0.012867805,0.000018875937,0.95483816,0.0001939179],"about_ca_topic_score_codex":0.4014521,"about_ca_topic_score_gemma":0.19630449,"teacher_disagreement_score":0.5831145,"about_ca_system_score_codex":0.00043794757,"about_ca_system_score_gemma":0.004159797,"threshold_uncertainty_score":0.81836087},"labels":[],"label_agreement":null},{"id":"W4252155602","doi":"10.2165/00128413-200515050-00055","title":"Product approvals in Canada","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Product (mathematics); Family medicine","score_opus":0.3203988441390227,"score_gpt":0.41083534119179926,"score_spread":0.09043649705277657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252155602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7953177,0.0037430162,0.00017952749,0.17824359,0.0010646998,0.0008749468,0.00019973473,0.000054985027,0.020321779],"genre_scores_gemma":[0.97444224,0.000063036256,0.0014385707,0.021491453,0.0007750872,0.00011082806,0.000016294558,0.000030535524,0.0016319708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957421,0.00016222348,0.0029687423,0.00053864974,0.00009773088,0.0004905835],"domain_scores_gemma":[0.99819446,0.00028103217,0.00088770513,0.00043187424,0.000033530076,0.00017141113],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0067380033,0.00016905967,0.0006705902,0.00023251568,0.00007305752,0.00003970292,0.00031816086,0.000047729645,0.0011687124],"category_scores_gemma":[0.0010697902,0.00022839518,0.00005329768,0.00023915732,0.000025736104,0.00046411168,0.00004282205,0.00021155905,0.0026651223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024780482,0.00020024712,0.31026337,0.00034215537,0.000069160546,0.000011282783,0.0018066632,0.0032562842,0.000038293954,0.021582806,0.656143,0.006261947],"study_design_scores_gemma":[0.001215195,0.000018527202,0.09317372,0.00004214547,0.0000029644275,0.000011451106,0.0005887355,0.008325915,0.0001438573,0.0017622141,0.89420277,0.0005124925],"about_ca_topic_score_codex":0.721342,"about_ca_topic_score_gemma":0.72873336,"teacher_disagreement_score":0.23805976,"about_ca_system_score_codex":0.0023025805,"about_ca_system_score_gemma":0.0010620696,"threshold_uncertainty_score":0.99974436},"labels":[],"label_agreement":null},{"id":"W4252472898","doi":"10.2165/00128413-200213410-00052","title":"Recent product approvals in Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Product (mathematics); Family medicine","score_opus":0.44171867976148776,"score_gpt":0.3969668101560449,"score_spread":0.04475186960544286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252472898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65023726,0.020330887,0.00009282116,0.27571407,0.0028748603,0.0015571824,0.00031500394,0.000085041094,0.048792906],"genre_scores_gemma":[0.9720256,0.0014612491,0.00058954756,0.022548797,0.0005138249,0.00016317827,0.000017590643,0.000042463776,0.0026377598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955932,0.00021229847,0.0029811396,0.0005842052,0.00011077235,0.0005183659],"domain_scores_gemma":[0.9980611,0.0002877304,0.0009409406,0.00047685785,0.000045055145,0.00018827079],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0054426985,0.00017954626,0.00069977663,0.0002331335,0.00008212489,0.00004249288,0.00031546285,0.000051033046,0.004564805],"category_scores_gemma":[0.0015805527,0.00024091486,0.00004855885,0.00033757128,0.000027263646,0.00033468893,0.000042664036,0.00022767273,0.0031341505],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000098457485,0.00017833691,0.13294163,0.00022544482,0.00004854942,0.000016242097,0.0013333268,0.00050134043,0.000011192115,0.0054392763,0.84867543,0.010619417],"study_design_scores_gemma":[0.00091472786,0.000020303238,0.031677384,0.000035665616,0.0000024785109,0.000009841606,0.0004515963,0.008823627,0.00004157899,0.0012402512,0.95637923,0.0004033088],"about_ca_topic_score_codex":0.5472576,"about_ca_topic_score_gemma":0.43080574,"teacher_disagreement_score":0.32178834,"about_ca_system_score_codex":0.002133506,"about_ca_system_score_gemma":0.0003918422,"threshold_uncertainty_score":0.99764204},"labels":[],"label_agreement":null},{"id":"W4253209358","doi":"10.2165/00128413-200213670-00012","title":"COX-2 inhibitor use increased after formulary listing in Canada","year":2002,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Medicine; Listing (finance); Pharmacy; Family medicine; Business","score_opus":0.016917552570486872,"score_gpt":0.22059349375602702,"score_spread":0.20367594118554014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253209358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974751,0.00047083528,0.000003377655,0.0003293037,0.00047842835,0.0003876663,0.000019842857,0.000046524907,0.0007889126],"genre_scores_gemma":[0.99528176,0.000017282193,0.00010627847,0.0036496883,0.000508588,0.00006391816,0.00001184244,0.000036372872,0.0003242631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985543,0.00006757736,0.00035098539,0.00023651283,0.00035062176,0.00043998825],"domain_scores_gemma":[0.9991599,0.00017908747,0.00006736744,0.00023240547,0.000058967194,0.0003022757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018042691,0.00019576731,0.00030711593,0.0001299654,0.000044378787,0.000020931031,0.000068486224,0.0000740232,0.0008350591],"category_scores_gemma":[0.00024300728,0.00017947207,0.00005821873,0.00021757865,0.000026313637,0.0002131034,0.000040888797,0.00033697966,0.00009799363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041295667,0.0001395309,0.9349154,0.00027736073,0.000037810325,0.007951808,0.00048185588,0.0000072273415,0.007915202,0.000005580137,0.04245549,0.005399767],"study_design_scores_gemma":[0.009918575,0.0002429884,0.8321705,0.0008139716,0.00013606006,0.00029088173,0.00015783134,0.016739912,0.02625604,0.000008126306,0.11246167,0.0008034385],"about_ca_topic_score_codex":0.44661742,"about_ca_topic_score_gemma":0.32168412,"teacher_disagreement_score":0.124933295,"about_ca_system_score_codex":0.00051052956,"about_ca_system_score_gemma":0.00035748765,"threshold_uncertainty_score":0.91433114},"labels":[],"label_agreement":null},{"id":"W4254352082","doi":"10.2165/00128413-200816570-00002","title":"The 2008 clinical type 2 diabetes guidelines from the Canadian Diabetes Association (CDA) include the new class of DPP-IV* inhibitors.","year":2008,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Drug class; Diabetes mellitus; Internal medicine; Pharmacology; Endocrinology; Drug","score_opus":0.05587108759421896,"score_gpt":0.3279714595386067,"score_spread":0.27210037194438774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254352082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8655581,0.0052868957,9.429637e-7,0.12340935,0.0017389258,0.0007529889,0.00004147935,0.00005901748,0.0031522808],"genre_scores_gemma":[0.9754122,0.0018653373,0.00013337111,0.011096316,0.0024113704,0.000040453753,0.000103253806,0.000040771563,0.008896937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974491,0.00024923915,0.00079429534,0.00028676505,0.0006481974,0.00057242904],"domain_scores_gemma":[0.99680096,0.0015389569,0.0003745032,0.0006117979,0.00040769752,0.00026609335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012919802,0.00024510908,0.00041424014,0.00006061572,0.00067313237,0.0000675448,0.00045566104,0.00015893644,0.0001312183],"category_scores_gemma":[0.0016039846,0.00012207066,0.00024071748,0.000377514,0.00025831864,0.00010782481,0.00015498292,0.00037862998,0.00018610507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017506129,0.00005221519,0.4152302,0.0000040832247,0.00048218673,0.000004319903,0.0001537321,0.0000040696723,0.00014641983,0.000038057104,0.57424486,0.009622326],"study_design_scores_gemma":[0.0013515179,0.00020843689,0.31744012,0.00006372382,0.0004772244,3.63719e-7,0.00009887531,0.00039447457,0.0016066178,0.00031057437,0.6779058,0.00014225628],"about_ca_topic_score_codex":0.013283481,"about_ca_topic_score_gemma":0.024468856,"teacher_disagreement_score":0.11231304,"about_ca_system_score_codex":0.0002770172,"about_ca_system_score_gemma":0.0006495944,"threshold_uncertainty_score":0.993332},"labels":[],"label_agreement":null},{"id":"W4254520879","doi":"10.2165/00128413-200514750-00059","title":"Abbott Laboratories' lansoprazole [Prevacid] has been approved in Canada","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lansoprazole; Pharmacy; Family medicine; Internal medicine","score_opus":0.26345220313296047,"score_gpt":0.38452366458628245,"score_spread":0.12107146145332198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254520879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77834374,0.0046194983,0.0005969518,0.19933178,0.0014768365,0.0010333578,0.0011715692,0.00010927839,0.013317014],"genre_scores_gemma":[0.97227824,0.00008768141,0.0014639474,0.024151647,0.00076580246,0.0001369934,0.0000529934,0.000048667112,0.0010140315],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99531054,0.00019813371,0.0031446656,0.00058095966,0.00013891966,0.00062676513],"domain_scores_gemma":[0.997704,0.0003988055,0.001037602,0.0005100726,0.00007568777,0.00027379475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005183524,0.00024694955,0.0008648125,0.00023970378,0.00015325147,0.000106783424,0.00043475392,0.00012047538,0.0010983518],"category_scores_gemma":[0.00094648736,0.0003393469,0.00006309992,0.0004046118,0.000049232283,0.0006769437,0.00006394281,0.0003258462,0.0021231119],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004853144,0.00022243457,0.37876794,0.00038135113,0.00011929994,0.000020993002,0.0036334218,0.0018590606,0.000076404576,0.0228466,0.5900062,0.0020178112],"study_design_scores_gemma":[0.0015695456,0.000022881923,0.053,0.000038560203,0.000004720082,0.000005227947,0.0010330142,0.0069989557,0.000116619354,0.0010560289,0.93565667,0.00049776543],"about_ca_topic_score_codex":0.6653524,"about_ca_topic_score_gemma":0.808669,"teacher_disagreement_score":0.34565052,"about_ca_system_score_codex":0.0024653035,"about_ca_system_score_gemma":0.0017983478,"threshold_uncertainty_score":0.9999059},"labels":[],"label_agreement":null},{"id":"W4255149466","doi":"10.2165/00128413-200715780-00050","title":"Health Canada advises of health risks with EMPowerplus","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Environmental health; Family medicine","score_opus":0.04979907539551033,"score_gpt":0.35108238039091794,"score_spread":0.3012833049954076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255149466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5644956,0.0018864891,0.0016765088,0.38923958,0.0018447513,0.00090694666,0.00004859931,0.00020250808,0.039699],"genre_scores_gemma":[0.8513342,0.000051794774,0.00015348065,0.14779906,0.0005475868,0.0000046847963,0.00002827577,0.000020653162,0.000060265218],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974374,0.000048156966,0.0008871531,0.0002620621,0.00032108036,0.0010441554],"domain_scores_gemma":[0.9984884,0.000121919955,0.0008550766,0.00024823705,0.00018269692,0.000103666294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023818947,0.00019779461,0.00058971834,0.00017381377,0.00025021893,0.000026279145,0.00026747465,0.00004884769,0.00012556626],"category_scores_gemma":[0.00014841363,0.00016095066,0.00004446297,0.00056482357,0.00008143978,0.00028223015,0.00009565787,0.00020388406,0.000025485322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006923448,0.00005786036,0.03385388,0.00050105585,0.00002563099,0.000010097759,0.000049122962,0.00030745953,0.0000027994338,0.0048031746,0.94034433,0.019975344],"study_design_scores_gemma":[0.0005617877,0.0000611551,0.10561156,0.000056405792,0.0000054307043,0.0000071399854,0.00072665664,0.00026364165,0.000002563071,0.00008504799,0.8924723,0.00014625443],"about_ca_topic_score_codex":0.983823,"about_ca_topic_score_gemma":0.7031225,"teacher_disagreement_score":0.2868386,"about_ca_system_score_codex":0.00020332837,"about_ca_system_score_gemma":0.0012874817,"threshold_uncertainty_score":0.65633774},"labels":[],"label_agreement":null},{"id":"W4255248028","doi":"10.2165/00128413-200515060-00058","title":"Cetuximab [Erbitux; Bristol-Myers Squibb, ImClone Systems] injection has been approved by Health Canada's Biologics and Genetic Therapeutics Directorate","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bristol-Myers; Cetuximab; Family medicine; Pharmacy; Pharmacology; Internal medicine; Cancer","score_opus":0.2486589550439336,"score_gpt":0.37565794022969595,"score_spread":0.12699898518576236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255248028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7579746,0.060564872,0.0043211053,0.16953081,0.0022108036,0.0020943817,0.002101061,0.00023408326,0.0009682692],"genre_scores_gemma":[0.9745799,0.0013029347,0.0011203325,0.021319853,0.000635733,0.00012524526,0.00013152289,0.00006901373,0.00071548135],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945278,0.0005490814,0.0032527628,0.00079011807,0.00015021043,0.0007300121],"domain_scores_gemma":[0.9964825,0.00037615641,0.0022016307,0.0004655775,0.00009469996,0.00037947076],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043359254,0.00036357588,0.0011760566,0.00022193349,0.00049731665,0.00024234547,0.00030856227,0.0001990605,0.0000584212],"category_scores_gemma":[0.00024013824,0.00044745082,0.000074522584,0.0002609031,0.00013948487,0.00033163332,0.000065282475,0.00032213362,0.00019484396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012286403,0.00053255976,0.08712216,0.0014753698,0.0006220493,0.000008625257,0.0032869852,0.0038311929,0.00046502706,0.0026598442,0.88721883,0.0126544805],"study_design_scores_gemma":[0.0020814678,0.00028599158,0.018088631,0.00006888704,0.000022375041,0.00005410943,0.0009030132,0.03216196,0.000055220156,0.00026103694,0.9451971,0.00082019344],"about_ca_topic_score_codex":0.37473735,"about_ca_topic_score_gemma":0.091912545,"teacher_disagreement_score":0.28282478,"about_ca_system_score_codex":0.0020271628,"about_ca_system_score_gemma":0.0008571006,"threshold_uncertainty_score":0.9997977},"labels":[],"label_agreement":null},{"id":"W4255619675","doi":"10.2165/00128413-200112960-00010","title":"Antipsychotic polypharmacy in schizophrenia in Canada","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Polypharmacy; Medicine; Antipsychotic; Schizophrenia (object-oriented programming); Psychiatry; Pharmacy; Pharmacology; Family medicine","score_opus":0.02528746022205306,"score_gpt":0.30873497216507567,"score_spread":0.2834475119430226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255619675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958194,0.0011739185,0.0000024545543,0.006402539,0.00023066769,0.000503024,0.000009770869,0.000030394018,0.0020652874],"genre_scores_gemma":[0.9977389,0.00050279876,0.0003129213,0.0008225423,0.00013190824,0.000054441643,0.000019330935,0.000026975265,0.00039019738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981425,0.00007104372,0.00035338005,0.00033983515,0.00045973633,0.0006335438],"domain_scores_gemma":[0.9991989,0.000076751116,0.000038679085,0.0002755778,0.000037966212,0.0003720934],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015158864,0.0001994199,0.00032689967,0.00036646213,0.00003211025,0.000017124148,0.00014850034,0.00003824108,0.00091931864],"category_scores_gemma":[0.000048722388,0.00017834257,0.000053510503,0.0008060015,0.000032038424,0.00011089124,0.000036603637,0.0004372953,0.00016375123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01766971,0.0005336639,0.8928153,0.000040253202,0.00006458855,0.01485058,0.000059557387,0.000024410108,0.002425568,0.00007369478,0.0042758253,0.06716688],"study_design_scores_gemma":[0.023327414,0.0001120663,0.9695301,0.00012356867,0.00002092879,0.00043048582,0.000095898235,0.00092984183,0.0018294404,0.00015666462,0.0032484627,0.00019514219],"about_ca_topic_score_codex":0.73332083,"about_ca_topic_score_gemma":0.89255404,"teacher_disagreement_score":0.15923323,"about_ca_system_score_codex":0.00094549195,"about_ca_system_score_gemma":0.002460142,"threshold_uncertainty_score":0.999994},"labels":[],"label_agreement":null},{"id":"W4255733503","doi":"10.2165/00128413-200414370-00056","title":"Health Canada has approved a new two-dose regimen of Meningococcal group C conjugate vaccine [NeisVac-C; Shire Biologics]","year":2004,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Regimen; Shire; Pharmacy; Meningococcal vaccine; Pharmacology; Family medicine; Internal medicine; Virology; Immunology; Immunization","score_opus":0.024698739203132227,"score_gpt":0.26563162755062075,"score_spread":0.24093288834748852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255733503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98005635,0.0020294837,0.00020395096,0.014869839,0.0018095828,0.0005237851,0.00010729458,0.00012326111,0.00027646223],"genre_scores_gemma":[0.9975919,0.000103388506,0.00021781116,0.0008706976,0.00018534945,0.000025484156,0.00021526273,0.000025309724,0.0007647626],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982926,0.00016645348,0.0006004965,0.00038269823,0.000026985077,0.0005307278],"domain_scores_gemma":[0.9990665,0.00006999243,0.000345535,0.00032955938,0.000084165586,0.000104269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024467052,0.0002840406,0.0005973268,0.00010014229,0.00027567847,0.000023035323,0.00027334015,0.00016488932,0.00039626218],"category_scores_gemma":[0.000044506665,0.00023956152,0.000099523066,0.00024401714,0.00007888458,0.000116946525,0.000115660536,0.00033290542,0.00005607857],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066079275,0.00026289208,0.0017550213,0.000043132583,0.00031813796,0.0000064882915,0.00031978264,0.000054477066,0.9084707,0.0015571405,0.078968756,0.007582674],"study_design_scores_gemma":[0.026395982,0.0021596146,0.024280077,0.00017971416,0.00012846693,0.00044342477,0.000399911,0.000010133612,0.2142066,0.0010562486,0.7298416,0.00089824287],"about_ca_topic_score_codex":0.66422355,"about_ca_topic_score_gemma":0.2907636,"teacher_disagreement_score":0.6942641,"about_ca_system_score_codex":0.00019783518,"about_ca_system_score_gemma":0.0011617973,"threshold_uncertainty_score":0.9769035},"labels":[],"label_agreement":null},{"id":"W4256035456","doi":"10.2165/00128413-200715930-00041","title":"New Avastin safety info issued in Canada","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Traditional medicine; Family medicine; Optometry; Ophthalmology","score_opus":0.014390874321892982,"score_gpt":0.30848279498024395,"score_spread":0.294091920658351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256035456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9312113,0.0010545568,0.00016145506,0.009093858,0.0013266918,0.00051941886,0.000017239383,0.000057459172,0.056558043],"genre_scores_gemma":[0.98191595,0.00008196009,0.00037700686,0.0038682192,0.0005305755,0.0000057561983,0.000027398599,0.00001768565,0.013175434],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989043,0.000018069251,0.0003155456,0.00018099514,0.00020168745,0.00037943793],"domain_scores_gemma":[0.9993807,0.00011348205,0.00005164131,0.0001263598,0.000031147025,0.00029666565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016230295,0.00014012009,0.00025334855,0.000106003725,0.00002765037,0.0000042414163,0.000075248696,0.00004642361,0.0050387965],"category_scores_gemma":[0.000019010247,0.00013210936,0.000039628874,0.00027426003,0.000018046421,0.00004908177,0.000026052123,0.00021975969,0.00009685231],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031316348,0.00019812367,0.332806,0.00006177351,0.00015637762,0.003300289,0.0007032252,0.00003521197,0.016809905,0.00006214749,0.48003376,0.16270155],"study_design_scores_gemma":[0.007836393,0.00014945409,0.34274668,0.00003697489,0.00008430519,0.000112953996,0.00013158497,0.00005005446,0.016765015,0.000018014101,0.6318964,0.00017220153],"about_ca_topic_score_codex":0.89090914,"about_ca_topic_score_gemma":0.91752625,"teacher_disagreement_score":0.16252935,"about_ca_system_score_codex":0.0012161734,"about_ca_system_score_gemma":0.0021393914,"threshold_uncertainty_score":0.9958707},"labels":[],"label_agreement":null},{"id":"W4256130786","doi":"10.2165/00128413-200112980-00008","title":"Emergency oral contraception cost saving in Canada","year":2001,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Reproductive Health and Contraception","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Emergency contraception; Pharmacy; Oral contraception; Medical emergency; Family medicine; Family planning; Population; Environmental health; Research methodology","score_opus":0.035237739672485925,"score_gpt":0.3261805814117229,"score_spread":0.29094284173923696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256130786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667306,0.00069058983,0.00016694056,0.007606962,0.0008250634,0.0006577309,0.0000044221783,0.000033486907,0.0033417395],"genre_scores_gemma":[0.99650735,0.0006751143,0.000055171095,0.0009801417,0.00054319215,0.000061104234,0.00002207385,0.000015680092,0.001140183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867725,0.00006264803,0.00036330687,0.00027623022,0.000245238,0.0003753374],"domain_scores_gemma":[0.99941736,0.000016532653,0.00007754883,0.00018747803,0.000111881105,0.00018921836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002567897,0.000118594595,0.00021922325,0.00008213492,0.00005359697,0.0000051957513,0.00005040073,0.00004303874,0.0015719022],"category_scores_gemma":[0.00010175476,0.00011564663,0.00003529616,0.000271698,0.000014304028,0.00013876372,0.000010417146,0.00024808044,0.00007825944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005279066,0.00011065648,0.7778991,0.000051991028,0.000013995824,0.00023013506,0.00011706737,0.000043189662,0.018593138,0.000026158314,0.018770907,0.18361576],"study_design_scores_gemma":[0.0018300562,0.00006344676,0.90917253,0.000038514438,0.000019686113,0.00009926958,0.0002967722,0.0006812374,0.00030654192,0.000033022752,0.08733674,0.00012218115],"about_ca_topic_score_codex":0.65564686,"about_ca_topic_score_gemma":0.79470587,"teacher_disagreement_score":0.18349358,"about_ca_system_score_codex":0.000694978,"about_ca_system_score_gemma":0.0007315303,"threshold_uncertainty_score":0.9993408},"labels":[],"label_agreement":null},{"id":"W4256723626","doi":"10.2165/00128413-200716000-00066","title":"Dronabinol/cannabidiol [Sativex; Bayer, GW Pharmaceuticals] has been approved by Health Canada for adults with moderate to severe cancer pain","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dronabinol; Cannabidiol; Pharmacy; Cancer; Traditional medicine; Family medicine; Cannabis; Psychiatry; Internal medicine; Cannabinoid","score_opus":0.030749402716131444,"score_gpt":0.34557481624392733,"score_spread":0.31482541352779586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256723626","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47633088,0.0043422747,0.01644566,0.49051347,0.00053365313,0.009018331,0.0017259294,0.0002313242,0.0008584749],"genre_scores_gemma":[0.9307734,0.0001376129,0.00076147536,0.04192352,0.0005995189,0.0006985672,0.000215885,0.00016514889,0.024724908],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99557275,0.00016760506,0.00064579403,0.0008727094,0.0010680092,0.0016731196],"domain_scores_gemma":[0.9967556,0.000088921784,0.00016849404,0.00042109468,0.0007486653,0.0018172376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016908108,0.0004959888,0.00076376897,0.00018158682,0.0004098146,0.00008346993,0.00030249954,0.00010807577,0.0003212508],"category_scores_gemma":[0.00018169441,0.00040165425,0.0001267064,0.0005819919,0.00016301169,0.00012308924,0.00008484313,0.0006036528,0.000008375323],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007258872,0.00024964745,0.0008522465,0.0006589082,0.0002024685,0.00008506935,0.0011178451,0.00013219735,0.0043802722,0.000019068315,0.90681887,0.07822453],"study_design_scores_gemma":[0.010051058,0.0016979376,0.0025608724,0.00033916833,0.000080926526,0.000056397712,0.0018196768,0.0062760008,0.022919089,0.000014249142,0.95350075,0.0006838641],"about_ca_topic_score_codex":0.305087,"about_ca_topic_score_gemma":0.31325686,"teacher_disagreement_score":0.45444247,"about_ca_system_score_codex":0.0016438605,"about_ca_system_score_gemma":0.0059733116,"threshold_uncertainty_score":0.99984354},"labels":[],"label_agreement":null}]}